element_id,text,page_number,filename,chunk_id
bd0b776276cae656ff10b842564770c7,Article,1,app\data\tmp\ALD patent background + target paper.pdf,1
181beb7ff10536b60933c566db7b6738,Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease,1,app\data\tmp\ALD patent background + target paper.pdf,2
6e4131e1e7f336505f7bc747474d3375,"https://doi.org/10.1038/s41586-019-1742-x Received: 9 April 2019 Accepted: 2 October 2019 Published online: 13 November 2019

https://doi.org/10.1038/s41586-019-1742-x",1,app\data\tmp\ALD patent background + target paper.pdf,3
a03f68ff8e03b5498bacaa157710d3fd,"Received: 9 April 2019

Accepted: 2 October 2019

Published online: 13 November 2019",1,app\data\tmp\ALD patent background + target paper.pdf,4
ae8c0529e39788f71a222cc70fa2f1ab,"Yi Duan1,2,29, Cristina Llorente1,2,29, Sonja Lang1, Katharina Brandl3, Huikuan Chu1, Lu Jiang1,2, Richard C. White4, Thomas H. Clarke4, Kevin Nguyen4, Manolito Torralba5, Yan Shao6, Jinyuan Liu7, Adriana Hernandez-Morales8, Lauren Lessor9, Imran R. Rahman10, Yukiko Miyamoto1, Melissa Ly11, Bei Gao1, Weizhong Sun1, Roman Kiesel1, Felix Hutmacher1, Suhan Lee1, Meritxell Ventura-Cots12, Francisco Bosques-Padilla13, Elizabeth C. Verna14, Juan G. Abraldes15, Robert S. Brown Jr16, Victor Vargas17,18,",1,app\data\tmp\ALD patent background + target paper.pdf,5
54f3b478381273af6d8623e134872345,"Jose Altamirano17, Juan Caballería18,19, Debbie L. Shawcross20, Samuel B. Ho1,2, Alexandre Louvet21, Michael R. Lucey22, Philippe Mathurin21, Guadalupe Garcia-Tsao23,24, Ramon Bataller12, Xin M. Tu7, Lars Eckmann1, Wilfred A. van der Donk10,25,26, Ry Young8,9, Trevor D. Lawley6, Peter Stärkel27, David Pride1,11,28, Derrick E. Fouts4 & Bernd Schnabl1,2,28*",1,app\data\tmp\ALD patent background + target paper.pdf,6
93de733c78594997019bb9302194d0be,"Chronic liver disease due to alcohol-use disorder contributes markedly to the global burden of disease and mortality1–3. Alcoholic hepatitis is a severe and life-threatening form of alcohol-associated liver disease. The gut microbiota promotes ethanol- induced liver disease in mice4, but little is known about the microbial factors that are responsible for this process. Here we identify cytolysin—a two-subunit exotoxin that is secreted by Enterococcus faecalis5,6—as a cause of hepatocyte death",1,app\data\tmp\ALD patent background + target paper.pdf,7
c986531d5412f4e355298480deca8a43,"and liver injury. Compared with non-alcoholic individuals or patients with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E. faecalis. The presence of cytolysin-positive (cytolytic) E. faecalis correlated with the severity of liver disease and with mortality in patients with alcoholic hepatitis. Using humanized mice that were colonized with bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic effects of",1,app\data\tmp\ALD patent background + target paper.pdf,8
da47bac9e20147d5d975c6657db03f51,"bacteriophages that target cytolytic E. faecalis. We found that these bacteriophages decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our findings link cytolytic E. faecalis with more severe clinical outcomes and increased mortality in patients with alcoholic hepatitis. We show that bacteriophages can specifically target cytolytic E. faecalis, which provides a method for precisely editing the intestinal microbiota. A clinical trial with a larger cohort",1,app\data\tmp\ALD patent background + target paper.pdf,9
1dd4d1aa056150ab861d62a8faa3723a,"is required to validate the relevance of our findings in humans, and to test whether this therapeutic approach is effective for patients with alcoholic hepatitis.",1,app\data\tmp\ALD patent background + target paper.pdf,10
1d4d6a1605a2007d1c0d85a5d80fd024,"The most severe form of alcohol-related liver disease is alcoholic hepa- titis; mortality ranges from 20% to 40% at 1–6 months, and as many as 75% of patients die within 90 days of a diagnosis of severe alcoholic hepatitis7–9. Therapy with corticosteroids is only marginally effective9. Early liver transplantation is the only curative therapy, but is offered only at select centres and to a limited group of patients10.",1,app\data\tmp\ALD patent background + target paper.pdf,11
869164d59f10a08b99e4509d3187c4e1,Alcohol-related liver disease can be transmitted via faecal micro- biota4. We investigated the microorganisms and microbial factors that are responsible for this transmissible phenotype and for progression of alcohol-related liver disease.,1,app\data\tmp\ALD patent background + target paper.pdf,12
cf2fcc649a4aa8f5119ff580e42687c4,Cytolysin linked to increased mortality,1,app\data\tmp\ALD patent background + target paper.pdf,13
acb2c9360ceb581180f68fdf8236676a,We performed 16S ribosomal RNA (rRNA) gene sequencing to deter- mine whether chronic alcohol use and alcoholic hepatitis are associated,1,app\data\tmp\ALD patent background + target paper.pdf,14
355bbe3840b9052292a5143bc76ba246,A list of affiliations appears at the end of the paper.,1,app\data\tmp\ALD patent background + target paper.pdf,15
2e9dab8c9390b48d812be9a6ec4389c3,"with an altered composition of the faecal microbiota. Differences in faecal microbiota composition were noted in patients with alcohol-use disorder and alcoholic hepatitis, compared to subjects without alcohol- use disorder (controls) (Fig. 1a, Extended Data Fig. 1a, b, Supplementary Tables 1, 2). One substantial difference that we observed was an increase in the proportion of Enterococcus spp. in patients with alcoholic hepa- titis: in these patients, 5.59% of faecal bacteria were Enterococcus",1,app\data\tmp\ALD patent background + target paper.pdf,16
b6127ade3d8300705287b45e04a437e8,"spp. compared with almost none in controls (0.023%; for comparison, 0.004% of all reads were Enterococcus spp. in the Human Microbiome Project) or patients with alcohol-use disorder (0.024%). Faecal sam- ples from patients with alcoholic hepatitis had about 2,700-fold more E. faecalis than samples from controls, as measured by quantitative PCR (qPCR) (Extended Data Fig. 1c), which is consistent with the 16S rRNA sequencing results. About 80% of patients with alcoholic hepatitis are positive for",1,app\data\tmp\ALD patent background + target paper.pdf,17
1d3f1c4c0a4ee6e0b60b79ddb43e7bf8,E. faecalis in their faeces (Extended Data Fig. 1d).,1,app\data\tmp\ALD patent background + target paper.pdf,18
824d7425c39b56495c815061b2d40c9d,"Nature | www.nature.com | 1

1",1,app\data\tmp\ALD patent background + target paper.pdf,19
07772919795b420da5863f023dcc2dbf,Article,2,app\data\tmp\ALD patent background + target paper.pdf,20
7d898269e95c4b633bd08360cf42e5c8,a  Controls  0.2  Alcohol-use disorder  Alcoholic hepatitis  )  %  5  7  .  7  1  (     2  C  P  0.1  0  −0.1  –0.2 –0.1  0  0.1 0.2  PC1 (29.25%) ,2,app\data\tmp\ALD patent background + target paper.pdf,21
b76e80fd1206ce67d2018027fc1b3b48,‘m,2,app\data\tmp\ALD patent background + target paper.pdf,22
da1229b98c1bcdb4cece82773ee24e76,b,2,app\data\tmp\ALD patent background + target paper.pdf,23
efec994032fd225f90a791b5ebb07eb8,100  Cytolysin-negative  Cytolysin-positive  )  %  (  s  t  c  e  j  b  u  S  80  60  40  20  0  Controls  AUD  Alcoholic ,2,app\data\tmp\ALD patent background + target paper.pdf,24
25e832f0c5431535aa769a8eec045b42,ma,2,app\data\tmp\ALD patent background + target paper.pdf,25
355900ca90a1cbfc73c5d5a98a66bcd6,=,2,app\data\tmp\ALD patent background + target paper.pdf,26
1a71e0e050b355f7226f6b4f989e1aea,)  %  (  l  a  v  i  v  r  u  S  100  75  50  25  0  0  30  Cytolysin-negative  Cytolysin-positive  60  90  120  150  180  Time (d) ,2,app\data\tmp\ALD patent background + target paper.pdf,27
2d52a405a6c203691797c8d8bbbb42d0,d,2,app\data\tmp\ALD patent background + target paper.pdf,28
2496d335772faf17889588416e0cc39c,0.15  Cytolysin-negative  Cytolysin-positive ,2,app\data\tmp\ALD patent background + target paper.pdf,29
6c3130e7d1a6621ea63cbae328bf0c8b,"@

@",2,app\data\tmp\ALD patent background + target paper.pdf,30
c2ed7937bb58f3e1b8fba73777f0b090,"Fig. 1 | E. faecalis cytolysin is associated with mortality in patients with alcoholic hepatitis. a, 16S rRNA sequencing of faecal samples from controls (n = 14), patients with alcohol-use disorder (n = 43) or alcoholic hepatitis (n = 75). We use principal coordinate analysis (PCoA) based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between each group (P < 0.01). b, Percentage of subjects",2,app\data\tmp\ALD patent background + target paper.pdf,31
6dd219ed908c4c59b7cbfab7e8854573,"with faecal samples that were positive for both cylLL and cylLS DNA sequences (cytolysin-positive), in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. Statistically significant differences were detected between controls and patients with alcoholic hepatitis (P < 0.01), and between patients with alcohol- use disorder and patients with alcoholic hepatitis (P < 0.001). c, Kaplan–Meier curve of survival of patients with alcoholic",2,app\data\tmp\ALD patent background + target paper.pdf,32
a709bf3499c6988848ce4897d661d9e2,"hepatitis whose faecal samples were cytolysin-positive (n = 25) or cytolysin-negative (n = 54) (P < 0.0001). d, Core genome single-nucleotide polymorphism (SNP) tree of E. faecalis strains isolated from patients with alcoholic hepatitis (n = 93 strains, from 24 patients), showing phylogenetic diversity of cytolysin-positive (red) E. faecalis. Genomically identical isolates from the same patient were combined, and are shown as a single dot. Scale bar represents the nucleotide substitutions per",2,app\data\tmp\ALD patent background + target paper.pdf,33
ba5612ca95f6dcdf57d83d1570f779a2,"SNP site. P values are determined by permutational multivariate analysis of variance (PERMANOVA) followed by false discovery rate (FDR) procedures (a), two-sided Fisher’s exact test followed by FDR procedures (b) or two-sided log- rank (Mantel–Cox) test (c). The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",2,app\data\tmp\ALD patent background + target paper.pdf,34
8236d6f4a45db9070aab3b792e782f31,"The colonization of mice with E. faecalis induces mild hepatic stea- tosis and exacerbates ethanol-induced liver disease11, by mechanisms that are unclear. Cytolysin is a bacterial exotoxin (or bacteriocin) that is produced by E. faecalis12, and which contains two post-translationally modified peptides (CylLL′′ and CylLS′′) in its bioactive form6. The two peptides are encoded by two separate genes: cylLL and cylLS, respec- tively12. Cytolysin has lytic activity against not only Gram-positive",2,app\data\tmp\ALD patent background + target paper.pdf,35
8890a3f00951f718471d8f5072af1949,"bacte- ria, but also eukaryotic cells13. We detected cylLL and cylLS genomic DNA (cytolysin-positive) in faecal samples from 30% of patients with alco- holic hepatitis; none of the faecal samples from controls and only one sample from a patient with alcohol-use disorder was cytolysin-positive, as detected by qPCR (Fig. 1b). Importantly, 89% of cytolysin-positive patients with alcoholic hepatitis died within 180 days of admission, compared to only 3.8% of cytolysin-negative patients (P < 0.0001)",2,app\data\tmp\ALD patent background + target paper.pdf,36
bc8f233615d19d70a36352d87ee6321a,"(Fig. 1c). Among the cytolysin-positive patients, 72.2% (13 out of 18) died owing to liver failure (including complications related to liver",2,app\data\tmp\ALD patent background + target paper.pdf,37
408ce44958e3962024f3107d220ef5ec,2 | Nature | www.nature.com,2,app\data\tmp\ALD patent background + target paper.pdf,38
0392181db05b7974f9acf50f8165ac3b,"failure, such as gastrointestinal bleeding) (Supplementary Table 2). Infection was not associated with 30-day, 90-day or 180-day mortality (P = 0.403, 0.234 or 0.098) in patients with alcoholic hepatitis.",2,app\data\tmp\ALD patent background + target paper.pdf,39
125fa27675c7dc1c74c6ba771da29661,"Our univariate logistic and Cox regression of laboratory and clinical parameters found an association between the detection of cytolysin- encoding genes in faeces and the international normalized ratio (INR), platelet count, the model for end-stage liver disease (MELD) score, the sodium MELD score, the age, serum bilirubin, INR and serum creatinine (ABIC) score and death (Supplementary Table 3). In the multivariate Cox analysis, detection of cytolysin-encoding genes in faeces was associated with",2,app\data\tmp\ALD patent background + target paper.pdf,40
28081f7e7cb82b5c8666c25824fba687,"90-day (P = 0.004) and with 180-day mortality (P = 0.001) (Supple- mentary Table 3), even after we adjusted for the geographical origin of the patient, antibiotic treatment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. We found no multicollinear- ity between the detection of faecal cytolysin-encoding genes and these cofactors (variance inflation factor < 1.6), which indicates that cytolysin is an independent predictor of mortality in patients with alcoholic",2,app\data\tmp\ALD patent background + target paper.pdf,41
32d4969c47c1e3fc369dc552e626009d,"hepatitis. When we performed receiver-operating-characteristic curve analysis for 90-day mortality, cytolysin had an area under the curve of 0.81, which was superior to other widely used predictors for mortality in clinical practice (Extended Data Fig. 1e). On the basis of our findings, we propose that the detection of cytolysin may be a prognostic factor for more severe liver- related outcomes and increased risk of death, and a stronger predictor of mortality than MELD, ABIC and the",2,app\data\tmp\ALD patent background + target paper.pdf,42
1fdae98c778dbb45464fc118723f1ee7,discriminant function score.,2,app\data\tmp\ALD patent background + target paper.pdf,43
39b30348c242a73c1e4294a3e70be529,"To determine phylogeny of E. faecalis in patients with alcoholic hepatitis, we performed targeted culturing from stool samples. Whole- genome sequencing of 93 E. faecalis isolates revealed a broad phylo- genetic diversity of cytolysin-positive E. faecalis from patients with alcoholic hepatitis (Fig. 1d), which indicates that cytolysin production is a variable trait among E. faecalis isolates and that cytolysin is car- ried in mobile genetic elements, which include both chromosomally encoded",2,app\data\tmp\ALD patent background + target paper.pdf,44
34b124c17a123293a0643101d3f1cdfa,pathogenicity islands and plasmids14. Detection of any other antimicrobial resistance genes or virulence genes in E. faecalis isolates did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Table 4).,2,app\data\tmp\ALD patent background + target paper.pdf,45
4b6395ab8114c45543d1c2a095bfdb47,"The total amount of faecal E. faecalis, or faecal E. faecalis positivity, did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Tables 5, 6). Cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis had similar amounts of faecal E. faecalis (Extended Data Fig. 1f). Although there were differences in the composition of the gut microbiota in patients with alcoholic hepatitis from different geographical regions (Extended Data",2,app\data\tmp\ALD patent background + target paper.pdf,46
18943a3648f1c7fe270fe0fc26e18f72,"Fig. 1g), the proportion of cytolysin-positive patients, total amount of faecal E. faecalis, faecal E. faecalis positivity (Extended Data Fig. 1h–j), treatment and clinical outcomes (30-day and 90-day mortality) did not differ significantly among the regions or centres (Supplemen- tary Table 7). In addition, cirrhosis was not associated with cytolysin positivity, the total amount of faecal E. faecalis or faecal E. faecalis positivity in patients with alcoholic hepatitis (Extended Data Fig. 1k–m,",2,app\data\tmp\ALD patent background + target paper.pdf,47
9aeaa18078f5638497cff51d50ec94ea,Supplementary Tables 4–6). These results confirm our findings that the presence of cytolysin-producing E. faecalis rather than the total amount or presence of E. faecalis per se determines the severity of alcoholic hepatitis and mortality.,2,app\data\tmp\ALD patent background + target paper.pdf,48
a0f350b3f5f7844e05183692cb0569ff,Cytolysin and ethanol-induced liver disease,2,app\data\tmp\ALD patent background + target paper.pdf,49
893a24833f49df5bf23bd55d24fb3acf,"To determine whether cytolysin contributes to liver damage mediated by E. faecalis, we gavaged mice with a cytolytic E. faecalis strain (FA2- 2(pAM714)) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5; the mice were then placed on a chronic–binge ethanol diet15. Compared to mice gavaged with phosphate-buffered saline (PBS), mice fed with ethanol after they were gavaged with cytolytic E. faecalis developed more severe liver injury as indicated by a higher level of alanine amino-",2,app\data\tmp\ALD patent background + target paper.pdf,50
9722753fc66339fd9d94d1c1bff8c490,"transferase (ALT) (Extended Data Fig. 2a) and increased hepatic stea- tosis (Extended Data Fig. 2b, c). Mice that were fed ethanol after they",2,app\data\tmp\ALD patent background + target paper.pdf,51
5468264cf01a478e9e050b33e418d5d9,")  1  –  l     U  (     T  L  A     f  o  400  300  200  100  0  *  ***  ***  **  Control  Ethanol 

b  e  d  i  r  e  c  y  l  g  i  r  t     c  i  t  a  p  e  H  )  r  e  v  i  l     g     r  e  p     g  m  (     t  n  e  t  n  o  50  40  30  20  10  0  ****  ****  ***  *  c  Control  Ethanol ",3,app\data\tmp\ALD patent background + target paper.pdf,52
75e8c013e785dd26cc53029982054f21,c  Control  Ethanol  Alcoholic hepatitis  cytolysin-positive  Alcoholic hepatitis  cytolysin-positive  Alcoholic hepatitis  cytolysin-negative  Alcoholic hepatitis  cytolysin-negative  no. 1  no. 2  no. 3  no. 4 ,3,app\data\tmp\ALD patent background + target paper.pdf,53
8d19536358be7fdf6676e2e4d2fdde8b,e,3,app\data\tmp\ALD patent background + target paper.pdf,54
73e1d00d83299f76ca50d0afd2830b1c,Cxcl1  e  g  n  a  h  c  d  l  o  F  8  6  4  2  **  **  **  **  0  Control  Ethanol ,3,app\data\tmp\ALD patent background + target paper.pdf,55
befa2b50fc52606b1d20275ebf3e6164,f,3,app\data\tmp\ALD patent background + target paper.pdf,56
e39c62f47ec3a196d10b8b599cd0310a,Col1a1,3,app\data\tmp\ALD patent background + target paper.pdf,57
c9f5124e5d78db081b5895c8306297bd,e  g  n  a  h  c  d  l  o  F  20  15  10  5  **  ***  *  *  0  Control  Ethanol ,3,app\data\tmp\ALD patent background + target paper.pdf,58
ae5b0525a446c1be33b9b61fb033216a,"h

LDH",3,app\data\tmp\ALD patent background + target paper.pdf,59
3f424982bcdcc97dd0b1edd7fa9fa3dd,)  %  40  *  *  **  **  (  y  t  i  c  i  x  o  30  20  t  o  t  10  y  C  0  0  0  0  200  0  400  200  200  400  400  0  0  0  200  0  400  200  200  400  400  CylLS″ (nM)  CylLL″ (nM)  –  +  Ethanol ,3,app\data\tmp\ALD patent background + target paper.pdf,60
cf2763830c3c584e0c36b4505205bb9d,B,3,app\data\tmp\ALD patent background + target paper.pdf,61
75c37220b082410dc30af0a40a25a936,Alcoholic hepatitis cytolysin-positive no. 1,3,app\data\tmp\ALD patent background + target paper.pdf,62
86065e7920b9736b8d341dd24c627766,B,3,app\data\tmp\ALD patent background + target paper.pdf,63
3250b65172f6c781a6ee7cff2087b9eb,Alcoholic hepatitis cytolysin-positive no. 2,3,app\data\tmp\ALD patent background + target paper.pdf,64
7dc75e80494f57917885fda5c8fa2312,B,3,app\data\tmp\ALD patent background + target paper.pdf,65
33e88bd5dd9c25a0ac1054922b63a858,Alcoholic hepatitis cytolysin-negative no. 3,3,app\data\tmp\ALD patent background + target paper.pdf,66
903390027e25750871c2c2d5c51a5dcd,B,3,app\data\tmp\ALD patent background + target paper.pdf,67
54d161ae19d6f6f6a9f3fbf64cdb0a24,"Alcoholic hepatitis cytolysin-negative no. 4

e  g  n  8  6  Il1b  *  *  **  **  a  h  c  d  l  o  F  4  2  0  Control  Ethanol ",3,app\data\tmp\ALD patent background + target paper.pdf,68
97f6fa61e02962b9d53262150f2a7b16,g,3,app\data\tmp\ALD patent background + target paper.pdf,69
b716582da73e1e01991cb2c7a0986495,)  %  (  e  c  i  M  100  80  60  40  20  ****  ****  ****  ****  0  ND ND ND  ND  ND ND  Control  Ethanol ,3,app\data\tmp\ALD patent background + target paper.pdf,70
c1e586063685bbb6421974f575ffc5a7,"Fig. 2 | Transplantation of faeces from cytolysin-positive patients with alcoholic hepatitis exacerbates ethanol-induced liver disease in gnotobiotic mice. a–g, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-positive and two cytolysin-negative patients with alcoholic hepatitis, and subjected to the chronic–binge feeding model. a, Serum levels of ALT. b, Hepatic triglyceride content. c, Representative sections of liver stained with haematoxylin and eosin (H & E). d–f,",3,app\data\tmp\ALD patent background + target paper.pdf,71
91fa7682bb03766e3814cac3887ced09,"Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. g, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. h, Lactate dehydrogenase (LDH) assay to measure cytotoxicity of hepatocytes isolated from mice that were fed an oral isocaloric control diet (five groups, left) or chronic–binge ethanol diet (five",3,app\data\tmp\ALD patent background + target paper.pdf,72
db6dcf00885c633bab6141bddf5939ba,"groups, right), and incubated with vehicle, CylLS′′, CylLL′′ or both of the cytolysin subunits at the indicated concentrations without (–) or with (+) ethanol (25 mM) for 3 h. The survival of hepatocytes was determined in three independent experiments. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h). P values are determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc test (a, b, d–f), two-sided Fisher’s exact test followed by FDR procedures (g) or",3,app\data\tmp\ALD patent background + target paper.pdf,73
60ee42870a79c938222aefaed67d72ad,"two-way ANOVA with Tukey’s post hoc test (h). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",3,app\data\tmp\ALD patent background + target paper.pdf,74
727095b18262f700549e050947003ce0,"were gavaged with cytolytic E. faecalis also had more liver inflamma- tion with higher expression levels of mRNAs that encode inflamma- tory cytokines and chemokines (Il1b, Cxcl1 and Cxcl2) (Extended Data Fig. 2d–f), compared with mice given PBS. Mice that were fed ethanol after they were gavaged with non-cytolytic E. faecalis had significantly less ethanol-induced liver injury, steatosis and inflammation (Extended Data Fig. 2a–f) and longer survival times (Extended Data Fig. 2g), as compared",3,app\data\tmp\ALD patent background + target paper.pdf,75
8f21e0f543c3754c299a5ee5982c2c25,with mice that were fed ethanol after they were administered with cytolytic E. faecalis.,3,app\data\tmp\ALD patent background + target paper.pdf,76
2127b2f050087bce85126a99d347b87f,"To explore the mechanism of cytolysin-associated liver damage, we measured cytolysin in the liver. CylLS was significantly increased in the liver of mice given cytolytic E. faecalis but not in the liver of mice that were not given E. faecalis or of mice gavaged with non-cyto- lytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2h). E. faecalis was detectable in the liver of mice given cytolytic and",3,app\data\tmp\ALD patent background + target paper.pdf,77
830dd5555f8f9975ed3e0c54a5e730f0,"non-cytolytic E. faecalis and fed an ethanol diet, but not when mice were fed an isocaloric (control) diet (Extended Data Fig. 2i); this indicates that ethanol-induced changes in the gut barrier are necessary for the translocation of cytolytic E. faecalis from the intestine to the liver. The livers of ethanol-fed mice that were given cytolytic or non-cytolytic E. faecalis had positive E. faecalis cultures (Extended Data Fig. 2j). We observed an increased intestinal permeability in ethanol-fed",3,app\data\tmp\ALD patent background + target paper.pdf,78
170d74a06c893e3c3b2f837608887dfd,"mice com- pared with mice fed with an isocaloric diet, but this was independent of gavaging cytolytic or non-cytolytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2k), indicating that cytolysin does not affect intestinal barrier function.",3,app\data\tmp\ALD patent background + target paper.pdf,79
1a4814caa5c7add9a98d7c7646213514,"Administration of cytolytic or non-cytolytic E. faecalis to mice did not significantly change the composition of the intestinal microbiota, as shown by 16S rRNA gene sequencing (Extended Data Fig. 2l). Cytolytic E. faecalis did not affect intestinal absorption or hepatic metabolism",3,app\data\tmp\ALD patent background + target paper.pdf,80
eecc5da894486333ba77cc535c72c685,"Nature | www.nature.com | 3

3",3,app\data\tmp\ALD patent background + target paper.pdf,81
b917675141c0dd5cc074f88942d8d114,Article,4,app\data\tmp\ALD patent background + target paper.pdf,82
99cbc110f9db5c2ef40a70ebbdf7cc28,a  Ef5.1  Ef5.2  Ef5.3  Ef5.4  Ef2.1  Ef2.2  Ef2.3 ,4,app\data\tmp\ALD patent background + target paper.pdf,83
49624c4f340527ff982100ee6692847e,b,4,app\data\tmp\ALD patent background + target paper.pdf,84
6c3c63bc0d386e2e4320082e6d77cdc0,s  l  e  v  e  l     m  u  r  e  S  )  1  –  l     U  (     T  L  A     f  o  400  300  200  100  0  Patient  no. 5  Patient  no. 2  *  Patient  no. 5  **  Patient  no. 2 ,4,app\data\tmp\ALD patent background + target paper.pdf,85
9fa3742ee6efd0d8b3ffde83cfed7cf6,c  e  d  i  r  e  c  y  l  g  i  r  t     c  i  t  a  p  e  H  )  r  e  v  i  l     g     r  e  p     g  m  (     t  n  e  t  n  o  c  50  40  30  20  10  0  Patient  no. 5  Patient  no. 2  *  Patient  no. 5  **  Patient  no. 2  C. crescentus phages  Cytolysin-positive E. faecalis  phages  C. crescentus phages  Cytolysin-positive E. faecalis  phages ,4,app\data\tmp\ALD patent background + target paper.pdf,86
7793102dc80ec3b8a1a9fcdaf161448d,"m

m

m

=",4,app\data\tmp\ALD patent background + target paper.pdf,87
cbc5068cea6993f78974702018fc164d,d  Control  Ethanol  C. crescentus  phages  Cytolysin-positive   E. faecalis phages  C. crescentus phages  Cytolysin-positive  E. faecalis phages ,4,app\data\tmp\ALD patent background + target paper.pdf,88
598c539ddcc632028f16116204d41baf,"Patient no. 5

Patient no. 2",4,app\data\tmp\ALD patent background + target paper.pdf,89
bf81bbaaebca57f294d15cb10c2c6e22,"f

e g n a h c d l o F",4,app\data\tmp\ALD patent background + target paper.pdf,90
05c4da49b02fbffda5cf14a3f97bc08a,12,4,app\data\tmp\ALD patent background + target paper.pdf,91
fc68a251e616fc88b7dda0f3815cf68a,RN onvbO®ON,4,app\data\tmp\ALD patent background + target paper.pdf,92
4860c78252e535cabd0a4715c13b409d,"8

6

4

2",4,app\data\tmp\ALD patent background + target paper.pdf,93
2ff46f566b5e1e7c70faf8e6b01acf9b,0,4,app\data\tmp\ALD patent background + target paper.pdf,94
91eee6c4548fb675d82668fe36b9934f,Patient no. 5,4,app\data\tmp\ALD patent background + target paper.pdf,95
9de2bc213241bec22e7310aba27297d9,Cxcl1,4,app\data\tmp\ALD patent background + target paper.pdf,96
a922061c4b16b5ba548b9738be05ba3b,"**

L",4,app\data\tmp\ALD patent background + target paper.pdf,97
d39fffdef448565aa8d231d99ca78977,"Patient no. 2

Patient no. 5",4,app\data\tmp\ALD patent background + target paper.pdf,98
1f5845cb12a00395a97b16beb5075afa,"**

]",4,app\data\tmp\ALD patent background + target paper.pdf,99
ddfba1144a293d44b82e266e5ee4bb03,"Patient no. 2

g  Col1a1  e  g  n  a  h  c  d  l  o  F  18  15  12  9  6  3  0  *  *  Patient      no. 5  Patient      no. 2  Patient      no. 5  Patient      no. 2  Control  Ethanol ",4,app\data\tmp\ALD patent background + target paper.pdf,100
e1062041fad0d6fc60bb7fc92811a2e9,Control,4,app\data\tmp\ALD patent background + target paper.pdf,101
6e5289caa3ed0da1b726fd9c18a659ba,"Ethanol

e  e  g  n  a  h  c  d  l  o  F  12  10  8  6  4  2  0  Il1b  *  ***  Patient      no. 5  Patient      no. 2  Patient      no. 5  Patient      no. 2  Control  Ethanol 

h  Liver cylLS  )  %  (  e  c  i  M  100  80  60  40  20  0  ND ND ND ND  **  **  Patient  no. 5  Patient  no. 2  Patient  no. 5  Patient  no. 2  Control  Ethanol ",4,app\data\tmp\ALD patent background + target paper.pdf,102
a12286cb0185c0addd5bea0688e4ca4b,"Fig. 3 | Phage therapy against cytolytic E. faecalis abolishes ethanol-induced liver disease in gnotobiotic mice. a, Transmission electron microscopy revealed that the phages we isolated were either siphophages (Ef5.1, Ef5.2, Ef5.3, Ef5.4 and Ef2.2) or myophages (Ef2.1 and Ef2.3). Scale bar, 50 nm. b–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin- positive patients with alcoholic hepatitis (faeces from one of these patients were also used in Fig. 2) and subjected to the",4,app\data\tmp\ALD patent background + target paper.pdf,103
0b7e4f0efad1916091e1a05109c7ff77,"chronic–binge feeding model, gavaged with control phages against C. crescentus (1010 plaque-forming units (PFUs)) or a cocktail of three or four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT.",4,app\data\tmp\ALD patent background + target paper.pdf,104
6319f0c7a1544988b2bbbb5fd6804989,"c, Hepatic triglyceride content. d, Representative H & E-stained liver sections. Scale bar, 100 μm. e–g, Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. h, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. Results are expressed as mean ± s.e.m. (b, c, e–g). P values are determined by two-way ANOVA with Tukey’s post hoc test (b, c, e–g) or two-sided Fisher’s exact test followed by FDR procedures (h). All results are generated from at least",4,app\data\tmp\ALD patent background + target paper.pdf,105
3dd6a8f102ce2440654dd2d64189d1f1,"three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, *** P < 0.001.",4,app\data\tmp\ALD patent background + target paper.pdf,106
09923dd9d1ffad44092a124abd15c8f7,"of ethanol, as indicated by serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs (which encode the two primary enzymes that metabolize ethanol in the liver) (Extended Data Fig. 2m, n). These results indicate that E. faecalis that produce cytolysin promote ethanol- induced liver disease in mice.",4,app\data\tmp\ALD patent background + target paper.pdf,107
7793aa12cd034679a8a2e84d767744db,"To extend our findings to humans, we colonized germ-free mice with faeces from cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis (Supplementary Table 8). Consistent with our findings from mice colonized with cytolytic E. faecalis, gnotobi- otic C57BL/6 mice colonized with faeces from two cytolysin-positive patients developed more severe ethanol-induced liver injury, steatosis, inflammation and fibrosis than mice given faeces from two cytolysin- negative patients (Fig.",4,app\data\tmp\ALD patent background + target paper.pdf,108
ac3153ad7dfb79bb025bd7847cd99080,"2a–f, Extended Data Fig. 3a–d). Transplantation of faeces from cytolysin-positive patients reduced the survival time of the mice (Extended Data Fig. 3e) and increased translocation of",4,app\data\tmp\ALD patent background + target paper.pdf,109
622a23d0c875953bf1e0ed086a86182e,4 | Nature | www.nature.com,4,app\data\tmp\ALD patent background + target paper.pdf,110
935baad085b120a079066df39fff470e,"cytolytic E. faecalis to the liver after ethanol administration (Fig. 2g). The overall composition of the intestinal microbiota was not differ- ent between mice fed the control diet and colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, as shown by 16S rRNA gene sequencing. Mice transplanted with faeces from one of the cytolysin-positive patients with alcoholic hepatitis (patient no. 2) showed a microbiota that was significantly different from",4,app\data\tmp\ALD patent background + target paper.pdf,111
011478f617a8cc488d426d6d9f3ef93c,"that of the other mouse groups after ethanol administration (Extended Data Fig. 3f). Non-cytolytic E. faecalis was not detected in stool samples from donors with cytolytic E. faecalis (Extended Data Fig. 3g). We did not observe differences in intestinal absorp- tion or hepatic metabolism of ethanol between mice colonized with faeces from cytolysin-positive versus cytolysin-negative patients (Extended Data Fig. 3h, i). Together, these results provide further evi- dence that cytolysin promotes",4,app\data\tmp\ALD patent background + target paper.pdf,112
ed6293163fbd16d348dc4294d76343bc,ethanol-induced liver disease.,4,app\data\tmp\ALD patent background + target paper.pdf,113
8aeff5253341209844ebbdb13999c971,a,5,app\data\tmp\ALD patent background + target paper.pdf,114
bfd469dd1341a1997f02b197216f8298,Ef6.1  Ef6.2  Ef6.3  Ef 6.4  Ef7.1  Ef7.2  Ef7.3  Ef 7.4 ,5,app\data\tmp\ALD patent background + target paper.pdf,115
ac18f49fc61400839bb6897862e288cc,"b

s l e v e l m u r e S",5,app\data\tmp\ALD patent background + target paper.pdf,116
6600ba9a1559abadee374ef041622e1a,400  300  200  100  0  Patient  no. 6  Patient  no. 7  Patient  no. 6  Patient  no. 7  Control  Ethanol ,5,app\data\tmp\ALD patent background + target paper.pdf,117
9df9b0747fd4fae53151630d240a82b3,"– l U ( T L A

( T L A f",5,app\data\tmp\ALD patent background + target paper.pdf,118
c9bdfc767b813466bcd5171874851118,e  d  i  r  e  c  y  l  g  i  r  t     c  i  t  a  p  e  H  )  r  e  v  i  l     g     r  e  p     g  m  (     t  n  e  t  n  o  c  50  40  30  20  10  0  Patient  no. 6  Patient  no. 7  Patient  no. 6  Patient  no. 7  Control  Ethanol ,5,app\data\tmp\ALD patent background + target paper.pdf,119
3c9ca1a477a08e8729484aa658bd1a3e,d,5,app\data\tmp\ALD patent background + target paper.pdf,120
4e7bf479eff4e39b80427279fed0f5fb,Control  Ethanol  C. crescentus  phages  Cytolysin-negative  E. faecalis phages  C. crescentus  phages  Cytolysin-negative  E. faecalis phages ,5,app\data\tmp\ALD patent background + target paper.pdf,121
28d3815936f1c0b0c0418a24b573aad6,"Patient no. 6

Patient no. 7",5,app\data\tmp\ALD patent background + target paper.pdf,122
1e7cda2ab93bd3819bc540c3e8d7e37f,e g n a h c d l o F,5,app\data\tmp\ALD patent background + target paper.pdf,123
9cd3d980272027712c9067242b4b3ed0,Cxcl1,5,app\data\tmp\ALD patent background + target paper.pdf,124
fd41f294467d39497310fc3e51a42801,"2N w A O ey &6 e - - Patient 6

Patient

Patient no. 6

g  Col1a1  h  6  e  g  n  a  h  c  d  l  o  F  4  2  0  Patient  Patient  Patient  Patient      no. 6      no. 7      no. 6      no. 7  Control  Ethanol ",5,app\data\tmp\ALD patent background + target paper.pdf,125
afe8c74c74d7b2920e59f43b72017a9f,Control,5,app\data\tmp\ALD patent background + target paper.pdf,126
749dc1a977f7d44f81e663dc0c456a14,Ethanol,5,app\data\tmp\ALD patent background + target paper.pdf,127
55b6c958b2963ffbd738b8801639e553,m,5,app\data\tmp\ALD patent background + target paper.pdf,128
3c993b05725a1229f20a7650070e9402,C. crescentus phages,5,app\data\tmp\ALD patent background + target paper.pdf,129
dfb1787d44412c8b5d0f6c64aa137a8e,=,5,app\data\tmp\ALD patent background + target paper.pdf,130
858440a4bf2da6c84ed2ca4e59d51ece,Cytolysin-negative E. faecalis phages,5,app\data\tmp\ALD patent background + target paper.pdf,131
8e7b4dbb2db0c289e4df104f330ddaf4,m,5,app\data\tmp\ALD patent background + target paper.pdf,132
b1a06f54aabc5d55fc83b36fdd1e7592,C. crescentus phages,5,app\data\tmp\ALD patent background + target paper.pdf,133
bfe93c268df64bfe9757e873cb7daa5e,m,5,app\data\tmp\ALD patent background + target paper.pdf,134
f19d51d0d477d6bad0a799914cdb8750,Cytolysin-negative E. faecalis phages,5,app\data\tmp\ALD patent background + target paper.pdf,135
823352a1c1b5b69a8e82cf0e4a521910,"e  g  n  a  h  c  d  l  o  F  5  4  3  2  1  0  Il1b  Patient      no. 6  Patient      no. 7  Patient      no. 6  Patient      no. 7  Control  Ethanol 

s  u  c  1010  *  *  c  o  c  o  r  e  t  n  E     l  a  c  )  1  –  g     U  F  C  (  109  108  107  106  e  a  F  105  Patient  Patient  Patient  Patient   no. 6  no. 7  no. 6  no. 7 ",5,app\data\tmp\ALD patent background + target paper.pdf,136
8bd70443573c2d3a2aefb595ced85a9d,"Fig. 4 | Phages that target non-cytolytic E. faecalis do not reduce ethanol- induced liver disease in gnotobiotic mice. a, Transmission electron microscopy revealed that the phages we isolated were either podophages (Ef6.2, Ef6.3, Ef7.2, Ef7.3 and Ef7.4) or siphophages (Ef6.1, Ef6.4 and Ef7.1). Scale bar, 50 nm. b–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis and subjected to the chronic–binge feeding model, gavaged with",5,app\data\tmp\ALD patent background + target paper.pdf,137
ff20ed0f63113aa14e50ddf829cd5669,control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages that target non-,5,app\data\tmp\ALD patent background + target paper.pdf,138
608c240755b516b9d1e17ee901ffe37e,"To determine the mechanism by which cytolysin increases liver dis- ease, we isolated hepatocytes from mice fed ethanol or control diets, and stimulated them with pure bioactive cytolysin peptides (CylLL′′ and CylLS′′)6. Incubation of the primary mouse hepatocytes with the two cytolysin subunits caused a dose-dependent increase in cell death compared to hepatocytes that were incubated with vehicle or with one subunit only (Fig. 2h). When we isolated hepatocytes from ethanol-fed mice and then",5,app\data\tmp\ALD patent background + target paper.pdf,139
2ae47261a8f4f2a945493ce8c56240bd,"incubated these hepatocytes with ethanol, we did not observe increased levels of cytolysin-induced cell death compared to hepatocytes isolated from mice on the control diet, which indicates that cytolysin-induced hepatocyte cell death was independent of ethanol. The cytotoxic effects of cytolysin are possibly mediated by pore forma- tion, resulting in cell lysis14.",5,app\data\tmp\ALD patent background + target paper.pdf,140
3630989dd32107d30ff2759948183c9c,Bacteriophage treatment in liver disease,5,app\data\tmp\ALD patent background + target paper.pdf,141
f2afe870ddcdac7775f5bab26fb2cd0d,"To further demonstrate the potential causative role of cytolytic E. faecalis for the development of ethanol-induced steatohepatitis,",5,app\data\tmp\ALD patent background + target paper.pdf,142
f66763778f39def107b37bed75a3106d,"cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT. c, Hepatic triglyceride content. d, Representative H & E-stained liver sections. Scale bar, 100 μm. e–g, Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. h, Faecal colony-forming units (CFUs) of Enterococcus. Results are expressed as mean ± s.e.m. (b, c, e–h). P values are determined by two-way ANOVA with Tukey’s post hoc test (b, c, e–h). All results were generated from at least three",5,app\data\tmp\ALD patent background + target paper.pdf,143
b2df314fc35d8fa26c1051b9fa5a9d52,independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05.,5,app\data\tmp\ALD patent background + target paper.pdf,144
8715ffa84565131d15d839daee7e92ea,"we investigated the effects of treatment with bacteriophages (here- after, phages). Phages are ubiquitous in bacteria-rich environments, including the gut16. E. faecalis phages that are highly strain-specific can be isolated17, which potentially makes the direct editing of gut microbiota feasible. It has previously been shown that Atp4aSl/Sl mice, which lack gastric acid, have overgrowth of intestinal enterococci, which is associated with increased susceptibility to alcohol-induced",5,app\data\tmp\ALD patent background + target paper.pdf,145
d4e4ebf06820627cde3000c0298e285d,steatohepatitis11. The gavaging of wild-type mice with an E. faecalis strain isolated from Atp4aSl/Sl mice led to increased ethanol-induced steatohepatitis11. We found that this same E. faecalis strain expressed cytolysin. We then isolated four distinct phages from sewage water. These phages lyse the cytolytic E. faecalis strain isolated from Atp4aSl/Sl mice. All four phages were podophages of the virulent Picovirinae group (Extended Data Fig. 4). Atp4aSl/Sl mice and their wild-type littermates,5,app\data\tmp\ALD patent background + target paper.pdf,146
da423fb9c9db6e5987449445350fb2b2,"were then placed on the chronic–binge ethanol diet and gavaged with the lytic phage cocktail. Phages directed against Caulobacter crescen- tus, a bacterium that is present in freshwater lakes and streams18 but that does not colonize humans or rodents19,20, were used as controls.",5,app\data\tmp\ALD patent background + target paper.pdf,147
ea534a783c4681a129bb59af62db150d,Nature | www.nature.com | 5,5,app\data\tmp\ALD patent background + target paper.pdf,148
1ffe452e18bc09e1d30504495cfa1d51,Article,6,app\data\tmp\ALD patent background + target paper.pdf,149
361cd1f8f40ff07ea4523bcd69039e90,"Compared to Atp4aSl/Sl mice gavaged with control phages or vehicle, Atp4aSl/Sl mice gavaged with phages that target cytolytic E. faecalis had less severe liver injury, steatosis and inflammation after chronic ethanol feeding (Extended Data Fig. 5a–f). Administration of E. faecalis phages significantly reduced levels of cytolysin in the liver (Extended Data Fig. 5g) as well as faecal amounts of Enterococcus (Extended Data Fig. 5h). Phage administration did not affect the overall composition of",6,app\data\tmp\ALD patent background + target paper.pdf,150
2e86acb1f126ec5ccc12959d9788b72a,"the faecal microbiome, intestinal absorption or hepatic metabolism of ethanol (Extended Data Fig. 5i–k).",6,app\data\tmp\ALD patent background + target paper.pdf,151
da944ce22ea102eea3d3575b7fe5c9ec,"To develop a therapeutic approach to precisely edit the intestinal microbiota, we cultured cytolytic E. faecalis strains from the faecal samples of patients with alcoholic hepatitis. We then isolated lytic phages from sewage water against these cytolytic E. faecalis strains; these phages had siphophage or myophage morphology (Fig. 3a, Extended Data Fig. 6). Gnotobiotic mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (Sup- plementary Table 8) and",6,app\data\tmp\ALD patent background + target paper.pdf,152
448ab979797c7f8c4bb555411515b529,"given three or four different—but patient- specific—lytic phages against cytolytic E. faecalis. The phages against cytolytic E. faecalis abolished ethanol-induced liver injury and steatosis, as shown by lower levels of ALT, lower percentages of hepatic cells positive for terminal deoxynucleotide transferase-mediated dUTP nick-end labelling, and lower levels of hepatic triglycerides and oil red O-staining (Fig. 3b–d, Extended Data Fig. 7a, b), as well as by decreased hepatic levels of Il1b,",6,app\data\tmp\ALD patent background + target paper.pdf,153
a801d5f342acb5a08914d264e9129efe,"Cxcl1, Cxcl2, Col1a1 and Acta2 mRNAs, and reduced hepatic levels of cylLS, as compared with mice given control phages (against C. crescentus) (Fig. 3e–h, Extended Data Fig. 7c, d). Treatment with phages against cytolytic E. faecalis also reduced faecal amounts of Enterococcus (Extended Data Fig. 7e) without affecting the overall composition of the gut microbiota (Extended Data Fig. 7f). Intestinal absorption of ethanol and hepatic metabolism were similar in all groups (Extended Data Fig. 7g, h).",6,app\data\tmp\ALD patent background + target paper.pdf,154
f75b8b93aa199fa22b781f6d65874fa1,"To demonstrate that the effect of phage treatment occurs via the targeting of cytolysin-positive E. faecalis, rather than a reduction in cytolysin-negative E. faecalis, we colonized gnotobiotic mice with faeces from cytolysin-negative patients with alcoholic hepatitis (Sup- plementary Table 8). Phages against non-cytolytic E. faecalis from patients were isolated from sewage water; they had siphophage or podophage morphology (Fig. 4a, Extended Data Fig. 8). These phages did not reduce features of",6,app\data\tmp\ALD patent background + target paper.pdf,155
8d9a5b3bad0d69a9dacfa8c0a75dd62f,"ethanol-induced liver disease compared with control phages (Fig. 4b–g, Extended Data Fig. 9a–h), despite the reduc- tion of faecal Enterococcus (Fig. 4h). Our findings indicate that treat- ment with lytic phages can selectively attenuate the ethanol-induced liver disease caused by cytolysin-positive E. faecalis in humanized mice.",6,app\data\tmp\ALD patent background + target paper.pdf,156
73345286028ac93b2aa305b02e6b8659,Discussion,6,app\data\tmp\ALD patent background + target paper.pdf,157
dcf9534bafefca952b6ef83708b06ecc,"Phage-based therapies have predominantly been studied in patients with bacterial infections in the gastrointestinal tract21–23, urinary tract24,25 and other organ systems26–28. The results of these studies— although mixed in terms of efficacy—strongly suggest that phage treat- ment offers a safe alternative to antibiotics26,27. However, safety studies are required for complex populations (such as patients with alcoholic hepatitis), because phages can induce a strong immune reaction29. Further",6,app\data\tmp\ALD patent background + target paper.pdf,158
9b306bb4dc6bbbaedaf26cc0b742b0ae,"work is required to determine whether phages that target cyto- lytic E. faecalis might be used to treat patients with alcoholic hepatitis, a life-threatening disease that at present has no effective treatment. Eradication of this specific bacterial strain might produce better out- comes than current treatments, and environmental sources can be used to easily isolate phages that target cytolysin-positive E. faecalis. Here we provide an example of the efficacy of approaches based on phages in mice",6,app\data\tmp\ALD patent background + target paper.pdf,159
4976ed9819fe07536b4aa8035c28de33,"for a disease that is not considered a classic infectious disease. Our data also suggest that cytolysin may be used as a predictive biomarker of severe alcoholic hepatitis; an independent, prospective",6,app\data\tmp\ALD patent background + target paper.pdf,160
28960f6fb27ff087b8dfab78cde778e1,"cohort is therefore needed to validate cytolysin as a biomarker, and to extend the phage findings in mice to human patients.",6,app\data\tmp\ALD patent background + target paper.pdf,161
b12b7ee72d2893362693758c1109328f,Online content,6,app\data\tmp\ALD patent background + target paper.pdf,162
664a0217f20d3bc1443ff751165b26cb,"Any methods, additional references, Nature Research reporting sum- maries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author con- tributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-019-1742-x.",6,app\data\tmp\ALD patent background + target paper.pdf,163
cf1eb66b1904b0bec30148649076d483,"1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).",6,app\data\tmp\ALD patent background + target paper.pdf,164
411a018af8d564bea7a3aecc980eeb32,"2. Lee, B. P., Vittinghoff, E., Dodge, J. L., Cullaro, G. & Terrault, N. A. National trends and long- term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern. Med. 179, 340–348 (2019).

3. Rehm, J. et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol. Clin. Exp. Res. 38, 1068–1077 (2014).",6,app\data\tmp\ALD patent background + target paper.pdf,165
3b20a4a7351a7e9f5f1e6e4278109178,"4. Llopis, M. et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65, 830–839 (2016).",6,app\data\tmp\ALD patent background + target paper.pdf,166
710d6370e4b44a5e2c9b6a80eec57bfe,"5. Ike, Y., Clewell, D. B., Segarra, R. A. & Gilmore, M. S. Genetic analysis of the pAD1 hemolysin/bacteriocin determinant in Enterococcus faecalis: Tn917 insertional mutagenesis and cloning. J. Bacteriol. 172, 155–163 (1990).",6,app\data\tmp\ALD patent background + target paper.pdf,167
4f0c34f00aef77d1830b1462a99a1b9a,"6. Tang, W. & van der Donk, W. A. The sequence of the enterococcal cytolysin imparts unusual lanthionine stereochemistry. Nat. Chem. Biol. 9, 157–159 (2013).",6,app\data\tmp\ALD patent background + target paper.pdf,168
cd5c6046e713db3d51bdaf81c30ed21f,"7. Maddrey, W. C. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75, 193–199 (1978).

8. Dominguez, M. et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103, 2747–2756 (2008).

9. Thursz, M. R. et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N. Engl. J. Med. 372, 1619–1628 (2015).

10. Mathurin, P. & Lucey, M. R. Management of alcoholic hepatitis. J. Hepatol. 56, S39–S45 (2012).",6,app\data\tmp\ALD patent background + target paper.pdf,169
b9520fac6b4b303b6d05de72326a6d03,"11. Llorente, C. et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat. Commun. 8, 837 (2017).",6,app\data\tmp\ALD patent background + target paper.pdf,170
ec0447525e244e6a7f4d5b23471b10ec,"12. Gilmore, M. S. et al. Genetic structure of the Enterococcus faecalis plasmid pAD1- encoded cytolytic toxin system and its relationship to lantibiotic determinants. J. Bacteriol. 176, 7335–7344 (1994).

13. Cox, C. R., Coburn, P. S. & Gilmore, M. S. Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. Curr. Protein Pept. Sci. 6, 77–84 (2005).",6,app\data\tmp\ALD patent background + target paper.pdf,171
e0368f951534f57823b7aa8168992669,"14. Van Tyne, D., Martin, M. J. & Gilmore, M. S. Structure, function, and biology of the Enterococcus faecalis cytolysin. Toxins 5, 895–911 (2013).",6,app\data\tmp\ALD patent background + target paper.pdf,172
ef518908f57cad07b83df52bfa3d8b0e,"15. Bertola, A., Mathews, S., Ki, S. H., Wang, H. & Gao, B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat. Protoc. 8, 627–637 (2013).",6,app\data\tmp\ALD patent background + target paper.pdf,173
8e57421c549867565d88dc4d073bc7e7,"16. Ogilvie, L. A. & Jones, B. V. The human gut virome: a multifaceted majority. Front. Microbiol. 6, 918 (2015).",6,app\data\tmp\ALD patent background + target paper.pdf,174
3803380998e2ae229a29082cd02f1b5c,"17. Chatterjee, A. et al. Bacteriophage resistance alters antibiotic-mediated intestinal expansion of enterococci. Infect. Immun. 87, e00085-19 (2019).

18. Poindexter, J. S. Biological properties and classification of the Caulobacter group. Bacteriol. Rev. 28, 231–295 (1964).",6,app\data\tmp\ALD patent background + target paper.pdf,175
b680f443c86e11e34523b28c27d4266e,"19. Shin, J. et al. Analysis of the mouse gut microbiome using full-length 16S rRNA amplicon sequencing. Sci. Rep. 6, 29681 (2016).",6,app\data\tmp\ALD patent background + target paper.pdf,176
68da42f61b419de03d06fd3ab7ebc055,"20. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).",6,app\data\tmp\ALD patent background + target paper.pdf,177
2a51dd1044d90657ff35ae613c06f10f,"21. Marcuk, L. M. et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull. World Health Organ. 45, 77–83 (1971).

22. Sarker, S. A. et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4, 124–137 (2016).",6,app\data\tmp\ALD patent background + target paper.pdf,178
461c601d17cffbdf0a89b31a807d27ad,"23. Dalmasso, M., Hill, C. & Ross, R. P. Exploiting gut bacteriophages for human health. Trends Microbiol. 22, 399–405 (2014).

24. Ujmajuridze, A. et al. Adapted bacteriophages for treating urinary tract infections. Front. Microbiol. 9, 1832 (2018).

25. Khawaldeh, A. et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol. 60, 1697–1700 (2011).",6,app\data\tmp\ALD patent background + target paper.pdf,179
1403e33338ced6564bf8f5ee94dd4e4b,"26. Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).

27. Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019).",6,app\data\tmp\ALD patent background + target paper.pdf,180
d94d8e1d29961cf0cf79b13d82ae0a07,"28. Fish, R. et al. Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials. Methods Mol. Biol. 1693, 159–170 (2018).",6,app\data\tmp\ALD patent background + target paper.pdf,181
f7ed0ef6e0d8d723b332561903ac824c,"effective step for moving toward clinical trials. Methods Mol. Biol. 1693, 159–170 (2018).

29. Górski, A. et al. Phages and immunomodulation. Future Microbiol. 12, 905–914 (2017).",6,app\data\tmp\ALD patent background + target paper.pdf,182
a737fa8f6bce1a5daab5b5eec38af4b1,"Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2019",6,app\data\tmp\ALD patent background + target paper.pdf,183
175fc1476066bd982efee48194e3aed1,6 | Nature | www.nature.com,6,app\data\tmp\ALD patent background + target paper.pdf,184
fd2edb8758b30b93d33427096a5f9aae,"1Department of Medicine, University of California San Diego, La Jolla, CA, USA. 2Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. 3Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA. 4J. Craig Venter Institute, Rockville, MD, USA. 5J. Craig Venter Institute, La Jolla, CA, USA. 6Host–Microbiota Interactions Laboratory, Wellcome Sanger Institute, Hinxton, UK. 7Division of Biostatistics and Bioinformatics,",7,app\data\tmp\ALD patent background + target paper.pdf,185
3ec392fa31016d664fbdb0bb14357069,"Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. 8Department of Biochemistry and Biophysics, Texas A & M University, College Station, TX, USA. 9Center for Phage Technology, Texas A & M AgriLife Research and Texas A & M University, College Station, TX, USA. 10Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA. 11Department of Pathology, University of California San Diego, La Jolla, CA, USA. 12Division of",7,app\data\tmp\ALD patent background + target paper.pdf,186
a00ed20e990458b7ac85ace42a650a08,"Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh Liver Research Center, Pittsburgh, PA, USA. 13Hospital Universitario, Departamento de Gastroenterología, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico. 14Division of Digestive and Liver Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. 15Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.",7,app\data\tmp\ALD patent background + target paper.pdf,187
1305768318ee7122785d1131186fb030,"16Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA. 17Liver Unit, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 18Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. 19Liver Unit, Hospital Clinic, Barcelona, Spain. 20Liver Sciences, Department of Inflammation Biology, School of Infectious Diseases and Microbial Sciences, King’s College London, London, UK.",7,app\data\tmp\ALD patent background + target paper.pdf,188
e2550b2353f7d195c411dc07902daa80,"21Service des Maladies de L’appareil Digestif et Unité INSERM, Hôpital Huriez, Lille, France. 22Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 23Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA. 24Section of Digestive Diseases, VA Connecticut Healthcare System, West Haven, CT, USA. 25Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana,",7,app\data\tmp\ALD patent background + target paper.pdf,189
0edc9c9f7c2eed23887414805507b9f5,"IL, USA. 26Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA. 27St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 28Center for Innovative Phage Applications and Therapeutics, University of California San Diego, La Jolla, CA, USA. 29These authors contributed equally: Yi Duan, Cristina Llorente. *e-mail: beschnabl@ucsd.edu",7,app\data\tmp\ALD patent background + target paper.pdf,190
74f6d39df933ea271406543d6fb85d7a,"Nature | www.nature.com | 7

7",7,app\data\tmp\ALD patent background + target paper.pdf,191
02184ce384cd3b6c78b3076c5fa7d93b,"Methods

Methods",8,app\data\tmp\ALD patent background + target paper.pdf,192
16445cb12dcc0f29f561143b247c13a1,No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment.,8,app\data\tmp\ALD patent background + target paper.pdf,193
5a601a4c0256b08c768412d4d61672bd,"Patient cohorts

Patient cohorts have previously been described** 2, We evaluated",8,app\data\tmp\ALD patent background + target paper.pdf,194
d6870f32a3cb28ebffd105a3da01da07,"26 subjects without alcohol-use disorder (controls; social drinkers consuming less than 20 g/day), 44 patients with alcohol-use disorder and 88 patients with alcoholic hepatitis. Patients with alcohol-use disorder fulfilling the DSM IV criteria33 of alcohol dependence and with active alcohol consumption (self-reported >60 g/day) presented with various stages of liver disease (21% had advanced F3/4 fibrosis based on fibrosis-4 index) (Supplementary Table 1). Patients with alcohol-use disorder",8,app\data\tmp\ALD patent background + target paper.pdf,195
ee6d7cc2d583ced2c6f5d39e8d21a40c,"were recruited from an alcohol withdrawal unit in San Diego and Brussels, where they followed a detoxification and rehabilitation programme. At admission to the hospital, a complete medication and medical history was taken, and a complete physical examination was performed, including collection of bio-specimens, basic demographic data (such as age, gender, weight and height) and self-reported daily alcohol consumption. Patients were actively drink- ing until the day of admission. Controls or",8,app\data\tmp\ALD patent background + target paper.pdf,196
916d2a71783f6bd538138e9788d24829,"patients with alcohol-use disorder did not take antibiotics or immunosuppressive medication during the two months preceding enrolment. Other exclusion criteria were diabetes, inflammatory bowel disease, known liver disease of any other aetiology, and clinically important cardiovascular, pulmonary or renal co-morbidities. Patients with alcoholic hepatitis were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centres in the USA, Mexico, UK, France and",8,app\data\tmp\ALD patent background + target paper.pdf,197
d42113fdf544402e302114480e63526b,"Spain. Inclusion criteria for this study were active alcohol abuse (>50 g/day for men and >40 g/day for women) in the past 3 months, aspartate aminotransferase (AST) > ALT and total bilirubin >3 mg/dl in the past 3 months, and a liver biopsy and/or clinical picture consistent with alco- holic hepatitis. Exclusion criteria were autoimmune liver disease (ANA >1/320), chronic viral hepatitis, hepatocellular carcinoma, complete portal vein thrombosis, extrahepatic terminal disease, pregnancy and a",8,app\data\tmp\ALD patent background + target paper.pdf,198
a204b7464918ba7a6608f2573b229958,"lack of signed informed consent. In all patients, the clinical picture was consistent with alcoholic hepatitis and in patients who underwent liver biopsy, the histology was consistent with the diagnosis of alco- holic hepatitis. Liver biopsies were only done if clinically indicated as part of routine clinical care for diagnostic purposes of alcoholic hepatitis. Bio-specimens were collected during their admission to the hospital. The median time of specimen collection was 4 days fol- lowing",8,app\data\tmp\ALD patent background + target paper.pdf,199
1c41fb0a246f0e06ea3abc9eeefcfc76,"admission to the hospital (range 0–24, n = 82). For one patient who underwent liver transplantation, the transplantation date was considered as date of death. Patients were censored at the time point at which they were last seen alive. The baseline characteristics are shown in Supplementary Tables 1, 2. Faecal 16S rRNA sequencing, Enterococcus culture and qPCR were performed. The MELD score, ABIC score and discriminant function were calculated from all alcoholic hepatitis patients from whom",8,app\data\tmp\ALD patent background + target paper.pdf,200
3ee65f6ab8dcf54c2784c53e0522ff5b,"respective laboratory values were avail- able. The protocol was approved by the Ethics Committee of Hôpital Huriez, Universidad Autonoma de Nuevo Leon, Hospital Universitari Vall d’Hebron, King’s College London, Yale University, University of North Carolina at Chapel Hill, Weill Cornell Medical College, Columbia University, University of Wisconsin, VA San Diego Healthcare System, University of California San Diego (UCSD) and Université Catholique de Louvain. Patients were enrolled after written",8,app\data\tmp\ALD patent background + target paper.pdf,201
43263a56eb1b8e340efa0fb1483f49bf,informed consent was obtained from each patient.,8,app\data\tmp\ALD patent background + target paper.pdf,202
e43e41e0724374e1ad25de889c5b6c81,"Mice

C57BL/6 mice were purchased from Charles River and used in Fig. 2h and Extended Data Fig. 2. C57BL/6 germ-free mice were bred at UCSD and used in Figs. 2a–g, 3, 4, Extended Data Figs. 3, 7 and 9. Sublytic Atp4aSl/Sl",8,app\data\tmp\ALD patent background + target paper.pdf,203
480750f58d2ad94cdcd813173376f03d,8 | Nature | www.nature.com,8,app\data\tmp\ALD patent background + target paper.pdf,204
29d2b22bddcd6c88af77bbbc47be6dc3,"mice on a C57BL/6 background have previously been described11,34 and heterozygous mice were used for breeding; sublytic Atp4aSl/Sl littermate mice and their wild-type littermates were used in Extended Data Fig. 5.",8,app\data\tmp\ALD patent background + target paper.pdf,205
41313bcdf6c3eb1b60374eb661ac7553,"Female and male mice (age of 9–12 weeks) were placed on a chronic– binge ethanol diet (NIAAA model) as previously described15. Mice were fed with Lieber–DeCarli diet and the caloric intake from ethanol was 0% on days 1–5 and 36% from day 6 until the end of the study period. At day 16, mice were gavaged with a single dose of ethanol (5 g/kg body weight) in the early morning and killed 9 h later. Pair-fed control mice received a diet with an isocaloric substitution of dextrose.",8,app\data\tmp\ALD patent background + target paper.pdf,206
8aa88d215f7c3fa0aadc29a2090e79d4,"Stool samples from patients with alcoholic hepatitis (Fig. 1) were used for faecal transplantation in germ-free mice. Mice were gavaged with 100 μl of stool samples (1 g stool dissolved in 30 ml Luria–Bertani (LB) medium containing 15% glycerol under anaerobic conditions), starting at an age of 5–6 weeks and repeated 2 weeks later. Two weeks after the second gavage, mice were placed on the ethanol or control (isocaloric) diet.",8,app\data\tmp\ALD patent background + target paper.pdf,207
845e6b656978e19dd6c856569ceff970,"In studies of the effects of cytolysin, 5 × 108 CFUs of a cytolytic E. fae- calis strain (FA2-2(pAM714)), a non-cytolytic E. faecalis strain (FA2- 2(pAM771))5 (E. faecalis Δcytolysin) (kindly provided by M. S. Gilmore), or PBS (vehicle control) were fed to mice by gavage every third day, starting from day 6 through day 15 of ethanol feeding. Administration every third day was necessary, given that E. faecalis does not colonize mice11 (Extended Data Fig. 2o). To determine the effect of phage",8,app\data\tmp\ALD patent background + target paper.pdf,208
1054838e9737e9cb259a76b46b11245f,"treat- ment, 1010 PFUs of E. faecalis phages (or C. crescentus phage phiCbK as control)35 were gavaged to the mice 1 day before the ethanol binge (at day 16). All animal studies were reviewed and approved by the Institu- tional Animal Care and Use Committee of UCSD.",8,app\data\tmp\ALD patent background + target paper.pdf,209
5d15b3fb08a9057f90c3b4590a744f7c,Bacteriophage isolation and amplification,8,app\data\tmp\ALD patent background + target paper.pdf,210
0cf8cff5a0f4518f3bedf341bb07b23b,"The E. faecalis strain from Atp4aSl/Sl mice faeces has previously been isolated11 and was used to isolate phages Efmus1, Efmus2, Efmus3 and Efmus4 (phages specific to the E. faecalis strain isolated from mouse faeces were named as Efmus with a number (Ef for E. faecalis, mus for mouse, digit for isolation order). E. faecalis strains from human stool samples were isolated using methods described below, and the cor- responding phages were named as Ef with patient number plus a digit (Ef for E.",8,app\data\tmp\ALD patent background + target paper.pdf,211
47736b938523c4219e8849406d8d238b,"faecalis, last digit for isolation order). All E. faecalis strains were grown statically in brain–heart infusion (BHI) broth or on BHI agar at 37 °C. C. crescentus phage phiCbK was purified as previously described35.",8,app\data\tmp\ALD patent background + target paper.pdf,212
84408ed45332c5df0373b4629e86f3cd,"E. faecalis phages were isolated from untreated raw sewage water obtained from North City Water Reclamation Plant in San Diego. Fifty millilitres of raw sewage water was centrifuged at 8,000g for 1 min at room temperature to pellet large particles. The supernatant was passed through a 0.45-μm and then a 0.2-μm syringe filter (Whatman, PES membrane). One hundred microlitres of the clarified sewage was mixed with 100 μl overnight E. faecalis culture and then added to BHI broth top agar (0.5% agar)",8,app\data\tmp\ALD patent background + target paper.pdf,213
1d3ddabf963b3d600ea967a70ac6cb60,"and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, the resulting plaques were recovered using a sterile pipette tip in 500 μl PBS. Phages were replaqued on E. faecalis three more times to ensure that the phages were clonal isolates.",8,app\data\tmp\ALD patent background + target paper.pdf,214
d9ee35db883c5c768306ff14e4034d64,"High-titre phage stocks were propagated by infecting 200 ml of expo- nentially growing E. faecalis at a multiplicity of infection of 0.1 in BHI broth containing 10 mM MgSO4. Lysis was allowed to proceed for up to six hours at 37 °C with shaking. The lysates were centrifuged at 10,000g for 20 min at room temperature to remove the remaining bacterial cells and debris. Supernatant was then vacuum-filtered through a 0.2-μm membrane filter and kept at 4 °C until use.",8,app\data\tmp\ALD patent background + target paper.pdf,215
ec2a1f94ca5d298f11fe51081ff9b80c,"Before mice were gavaged, 10–20 ml lysates were concentrated using Corning Spin-X UF Concentrators with 100,000-molecular weight cutoff (MWCO) to a volume of approximately 1 ml. Following concen- tration, the culture medium was replaced with PBS via diafiltration. The resulting lysate was further concentrated to a final volume of 0.5 ml and adjusted to the required PFUs.",8,app\data\tmp\ALD patent background + target paper.pdf,216
2b6cdd0d09ed98de2413c07c145050b4,Whole-genome sequencing for phages,9,app\data\tmp\ALD patent background + target paper.pdf,217
3c4a3bf05d0bbb830c0a46194db38a2b,"For all phages except Efmus4, 10 ml of lysates were treated with 10 μg/ml each of DNase and RNase at 37 °C for 1 h and phages were precipitated by adding 1M NaCl and 10% (w/v) polyethylene glycol 8000 (PEG 8000) and incubated at 4 °C overnight. Precipitated phages were then pel- leted by centrifugation at 10,000g for 10 min at 4 °C and resuspended in 500 μl of resuspension buffer (5 mM MgSO4). Phage DNA was then extracted using Promega Wizard DNA Clean-up kit (Promega). Phage genomes were",9,app\data\tmp\ALD patent background + target paper.pdf,218
a1f43ce701044322aedff9563a6291bd,sequenced using a combination of Illumina and Oxford Nanopore Technologies (ONT) MinION platforms. Illumina sequencing libraries were prepared using the Nextera XT library kit with bead-based size selection before loading onto Illumina flow cells. Sequencing was performed with either Illumina MiSeq Reagent Kit v3 in 2 × 300-bp or NextSeq 500 Mid Output Kit in 2 × 150-bp paired-end formats. ONT MinION sequencing libraries were prepared using the Rapid Barcoding Kit (SQK-RBK004) and loaded onto,9,app\data\tmp\ALD patent background + target paper.pdf,219
a5a94291ff968cc19d8d1adda7510cf0,"MinION R9.4 flow cells. ONT reads were basecalled with Albacore v.2.3.4 (ONT). The sequence reads were demultiplexed and adapters trimmed from ONT reads using Porechop v.0.2.336. A hybrid Illumina-ONT de novo assembly was performed using the Unicycler v.0.4.7 pipeline37. Subsequently, Pilon v.1.2238 was used iteratively to polish the assemblies with Illumina reads until no addi- tional corrections could be made.",9,app\data\tmp\ALD patent background + target paper.pdf,220
28b4970e53bc6fbef49128ac31fa73bf,"For phage Efmus4, 109 PFUs of the phage was filtered sequentially using 0.45-μm and 0.2-μm filters (VWR) and purified on a caesium chloride (CsCl) density gradient39. One millilitre of the CsCl fraction was purified on Amicon YM-100 protein columns (Millipore) and treated with DNase I. DNA was isolated using a Qiagen UltraSens virus kit (Qia- gen), amplified using GenomiPhi V2 (GE Healthcare), and fragmented to 200 to 400 bp using a Bioruptor (Diagenode). Libraries were created using the Ion",9,app\data\tmp\ALD patent background + target paper.pdf,221
e84b3a123771c3d583f2f1acc67a0244,"Plus fragment library kit and sequenced using a 316 Chip on an Ion Torrent Personal Genome Machine (Life Technologies). Reads were trimmed according to modified Phred scores of 0.5 using CLC Genomics Workbench 4.9 (Cambridge), and the remaining reads were assembled using CLC Genomics Workbench 4.9 based on 98% identity with a minimum of 50% read overlap39. Reads were assembled into a single contig of 18,186 bp (20,118 × coverage).",9,app\data\tmp\ALD patent background + target paper.pdf,222
6ddcabed12711b04086d2f0508485d2d,"Mapping of ONT reads to the hybrid assemblies was used to deter- mine the orientation and terminal ends of linear phage genomes, and reference genomes served as guides to orient circular phage genomes. Phage genome assemblies were annotated using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP)40,41.",9,app\data\tmp\ALD patent background + target paper.pdf,223
be0eca667178ce51d4f5a1fd44baaea1,"Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSample IDs (SAMN11089809– SAMN11089827). GenBank accession numbers include: Efmus1 (MK721195), Efmus2 (MK721197), Efmus3 (MK721185), Efmus4 (MK721193), Ef2.1 (MK693030), Ef2.2 (MK721189), Ef2.3 (MK721192), Ef5.1 (MK721199), Ef5.2 (MK721186), Ef5.3 (MK721200), Ef5.4 (MK721191), Ef6.1 (MK721187), Ef6.2 (MK721188), Ef6.3 (MK721196), Ef6.4 (MK721190), Ef7.1 (MK721194), Ef7.2 (MK721183), Ef7.3",9,app\data\tmp\ALD patent background + target paper.pdf,224
ee6f32773773f9923d3e2e3aa999e393,(MK721184) and Ef7.4 (MK721198).,9,app\data\tmp\ALD patent background + target paper.pdf,225
612303de3ad8f9d5cadbc10dde1a7a33,"Genetic maps of phage genomes were generated by LinearDisplay. pl (https://github.com/JCVenterInstitute/LinearDisplay), a PERL script that uses Xfig (https://sourceforge.net/projects/mcj/) to render high- quality images. Preliminary annotation of genes was derived from the automated annotation and from Phage_Finder42, which uses curated hidden Markov models and databases of core phage gene to annotate core gene functions. Annotation was then manually reviewed to assign the final colours.",9,app\data\tmp\ALD patent background + target paper.pdf,226
5d5e6804eb56552ba196cd145529f48c,"Phage phylogenetic tree

A phage whole-genome phylogeny tree was generated from a pairwise distance matrix calculated with the MASH program, which approxi- mates average nucleotide identity (ANI)43. First, a sketch file was created from all the 19 E. faecalis phage genomes isolated and sequenced in",9,app\data\tmp\ALD patent background + target paper.pdf,227
25567a23a991039d552cf007809beac7,"this study plus 54 Enterococcus phage genomes obtained from Gen- Bank, with 5,000 12-mers generated per genome (mash sketch -k 12 -s 5000). The sketch file was then compared to all the initial phage genome sequences to generate the ANI matrix using the mash distance command using default settings. The GGRaSP R package was used to calculate the UPMGA phylogeny from the ANI distance matrix, after redundant phage genomes (genomes ANI >99.985) were removed using the GGRaSP R package with a user",9,app\data\tmp\ALD patent background + target paper.pdf,228
458c6f1853a3abbb6256c5cd9373a36d,"defined cutoff of 0.015 (ggrasp. cluster (threshold = 0.015)). The resulting dendrogram was translated into newick format using the APE R package44, loaded into the iTOL tree viewer45, and annotated with taxonomic information and manually entered clade identification.",9,app\data\tmp\ALD patent background + target paper.pdf,229
279b1e0d27645678e147ba605f643e36,"Electron microscopy

Phage morphology was examined by transmission electron microscopy of negatively stained grids, prepared using the valentine method46 with either 2% uranyl-acetate or 2% phosphotungstic acid, and examined at an acceleration voltage of 100 kV in the JEOL 1200 EX transmission electron microscope.",9,app\data\tmp\ALD patent background + target paper.pdf,230
952678b8d3b62b06dd0cf70d0368ae98,Bacterial DNA extraction and 16S rRNA sequencing,9,app\data\tmp\ALD patent background + target paper.pdf,231
879e5679fc67a821c837ca23f5ccaac6,"DNA from human stool samples, mouse liver sections or bacterial cul- ture was extracted as previously described11, and DNA from mouse faeces was extracted using QIAamp Fast DNA Stool kit (Qiagen). 16S rRNA PCR was completed using Illumina adaptor and barcode-ligated 16S primers targeting the V4 region of the 16S rRNA gene47,48. Amplicons were purified using the Qiaquick PCR purification kit (Qiagen) using manufacturer’s specifications. Purified amplicons were then quantified via TECAN assay",9,app\data\tmp\ALD patent background + target paper.pdf,232
2c0ff59c0cd68219e7a48234c417cc24,"(Tecan), normalized and pooled in preparation for 16S rRNA sequencing. Pooled library was quantified and checked for qual- ity using Agilent 2100 Bioanalyzer (Agilent Technologies). Library was sequenced on Illumina MiSeq (Illumina) using V2 reagent chemistry, 500 cycles, 2 × 250-bp format using manufacturer’s specifications. 16S sequence reads were processed and operational taxonomic units were determined using our MOTHUR-based 16S rDNA analysis workflow as previously described11,49. Raw 16S",9,app\data\tmp\ALD patent background + target paper.pdf,233
f0d76cbecb21e9b36e2dd639148a1ffa,sequence reads can be found in the NCBI Sequence Read Archive (SRA) associated with Bioproject PRJNA525701.,9,app\data\tmp\ALD patent background + target paper.pdf,234
c997e7d141f4e397cf5e574a4ecb388f,Real-time qPCR,9,app\data\tmp\ALD patent background + target paper.pdf,235
f4b3d67f1685aad442a06d6ed900e08a,"Bacterial genomic DNA was extracted from human stool samples and mouse liver11. RNA was extracted from mouse liver and cDNAs were generated11. Primer sequences for mouse genes were obtained from the NIH qPrimerDepot. Primer sequences for E. faecalis 16S rRNA gene, E. faecalis cylLS and cylLL genes have previously been described50,51. All primers used in this study are listed in Supplementary Table 9. Mouse gene expression and amplification of bacterial genes were determined with Sybr Green",9,app\data\tmp\ALD patent background + target paper.pdf,236
3c15671b591c614cc9f98761bbb884c8,(Bio-Rad Laboratories) using ABI Ste- pOnePlus real-time PCR system. The qPCR value of mouse genes was normalized to 18S.,9,app\data\tmp\ALD patent background + target paper.pdf,237
fabca3851ffef2d593aeb9dc88be8a8d,E. faecalis isolation and whole-genome sequencing,9,app\data\tmp\ALD patent background + target paper.pdf,238
e2f9cff1f803bc112556e1900ca6323b,"To isolate E. faecalis strains from human subjects, 50–300 mg of human stool was resuspended in 500 μl PBS, serial dilutions were made and 100 μl was placed on plates with selective medium, BBL Enterococcosel broth (Becton Dickinson). Enterococci colonies were identified by the production of dark brown or black colour, generated by hydrolysis of esculin to esculetin (which reacts with ferric ammonium citrate). Each Enterococcus colony was then picked, and qPCR was performed to identify E.",9,app\data\tmp\ALD patent background + target paper.pdf,239
3051ce04a25e4f4fbeb2ca718e91415c,"faecalis, using specific primers against the E. faecalis 16S rRNA gene50. For each subject, between 1 and 6 E. faecalis colonies were analysed and bacterial genomic DNA was then extracted as described in ‘Bacterial DNA extraction and 16S rRNA sequencing’.",9,app\data\tmp\ALD patent background + target paper.pdf,240
c0e4193737db48b796ed87ddd42ddeef,DNA sequencing was performed on the Illumina HiSeq Ten X generat- ing paired-end reads (2 × 151 bp). Bacterial genomes were assembled,9,app\data\tmp\ALD patent background + target paper.pdf,241
54e2256698e823d01aae220797fae8ce,Article,10,app\data\tmp\ALD patent background + target paper.pdf,242
a81f5d95c8552032ee8ccf9515b4fa3a,"and annotated using the previously described pipeline52. Antimicrobial resistance and virulence genes including cytolysin (cyl) genes carried by E. faecalis isolates were identified by comparing individual genome assemblies against the CARD and VFDB databases, respectively, using abricate v0.8.10 (https://github.com/tseemann/abricate)53,54.",10,app\data\tmp\ALD patent background + target paper.pdf,243
48d1a63de8ada2b94a2834b820ad6b24,"For the phylogeny of E. faecalis, the genome assemblies of the study isolates were annotated with Prokka55, and a pangenome estimated using Roary52. A 95% identity cutoff was used, and core genes were defined as those in 99% of isolates. A maximum likelihood tree of the SNPs in the core genes was created using RAxML56 and 100 bootstraps. The resulting tree was visualized using iTOL45. Genome sequence data of E. faecalis strains isolated in this study have been deposited in the European",10,app\data\tmp\ALD patent background + target paper.pdf,244
0370a29007d04b3dd32bc2215a54fcdb,Nucleotide Archive (ENA) under the accession number PRJEB25007. Sequence reads are available at ENA under run acces- sion identifiers ERR3200171–ERR3200263.,10,app\data\tmp\ALD patent background + target paper.pdf,245
28fd82b737f33f6c4ebc9d5b0af7269c,"E. faecalis culture

All E. faecalis strains were grown statically in BHI broth or on BHI agar plate at 37 °C. Fifty micrograms per millilitre erythromycin was added when cytolytic and non-cytolytic E. faecalis strains were grown (Extended Data Fig. 2).",10,app\data\tmp\ALD patent background + target paper.pdf,246
457f7cdb5ab6e048efd1b9054b1dbfdb,Determination of levels of faecal Enterococcus,10,app\data\tmp\ALD patent background + target paper.pdf,247
e546f05e6b082db9fd0ad6bebbfd9628,"To determine levels of faecal enterococci in mice, 10–30 mg of mouse faeces was resuspended into 500 μl PBS and serial dilutions were made. Five microlitres of each dilution from each sample was spotted onto a plate with a selective medium, BBL enterococcosel broth (Becton Dickinson) and the plates were then incubated at 37 °C overnight. For Extended Data Fig. 2o, agar plates contained 50 μg/ml erythromycin. Enterococci colonies were identified by the production of a dark brown or black colour.",10,app\data\tmp\ALD patent background + target paper.pdf,248
9027ed082b48a9b599ba59929ef9fdac,"Colony numbers of each sample were then counted, and CFUs were calculated.",10,app\data\tmp\ALD patent background + target paper.pdf,249
36d0b175de183c348625031a47bb6909,Cytolysin expression and purification,10,app\data\tmp\ALD patent background + target paper.pdf,250
2bd44c96c891b4b04d30ef2ea8dcba56,"To purify bioactive CylLL′′ and CylLS′′, an Escherichia coli heterologous expression system was used. In brief, either 6×His–CylLL or 6×His–CylLS were co-expressed with CylM (the enzyme that performs dehydration and cyclization reactions on cytolysin) in E. coli to yield fully dehydrated and cyclized full-length peptides. The His tag and leader peptide were then removed using recombinant CylA (27–412), the soluble domain of the native peptidase used in cytolysin maturation, to yield bioactive",10,app\data\tmp\ALD patent background + target paper.pdf,251
ded3c7bab7c5deb1b39e237a29f3ad9d,CylLL′′ or CylLS′′. The resulting core peptides were further purified by reversed-phase high-performance liquid chromatography (HPLC).,10,app\data\tmp\ALD patent background + target paper.pdf,252
87e8f6d097173fd4dbb5a85c0acf31ad,"The cylLL and cylLS genes were previously cloned into the MCSI of a pRSFDuet-1 backbone vector that contained the cylM gene in MCSII6. The cylA (27–412) gene was previously cloned into MCSI of a pRSFDuet-1 backbone vector57. E. coli BL21 Star (DE3) cells (50 μl) were transformed with 100 ng of either the cylLL_cylM:pRSFDuet, cylLS_cylM:pRSFDuet or cylA (27–412):pRSFDuet plasmids via KCM chemical transformation. The cells were plated on LB agar plates supplemented with kanamycin (50 μg/ml) and",10,app\data\tmp\ALD patent background + target paper.pdf,253
39fc5f6a6259ecc7f05465096e620450,grown at 37 °C overnight. One colony was picked to inoculate 15 ml of LB broth supplemented with kanamycin overnight at 37 °C. The culture was used to inoculate 1.5 l of terrific broth supple- mented with kanamycin. Cultures were grown with shaking at 37 °C to an optical density at 600 nm (OD600) of 0.8. The temperature of the incu- bator was lowered to 18 °C and expression was induced with the addi- tion of 0.3 mM final concentration of isopropyl β-d-thiogalactoside. The cultures were allowed,10,app\data\tmp\ALD patent background + target paper.pdf,254
c228d920074c16544588eb9bd2b176b4,"to incubate at 18 °C for 18 h. The cells were collected by centrifugation at 5,000g for 12 min. The cell paste was collected and frozen at -70 °C.",10,app\data\tmp\ALD patent background + target paper.pdf,255
503de21eb39a91f2da527a381264e9b5,"For the purification of the protease CylA (27–412), the cell paste was thawed and resuspended in 50 ml LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5). The cell suspension was lysed by homogenization. The lysate was clarified by centrifugation at 13,000g for 45 min and filtered through a 0.45-μm centrifugal filter (Thermo Scientific). The clarified",10,app\data\tmp\ALD patent background + target paper.pdf,256
b8dac3915c21746d319a5273e6185c90,"lysate was applied to a pre-equilibrated HisTrap HP 5 ml column (GE Healthcare) through a peristaltic pump. The loaded column was con- nected to an ÄKTA pure 25 M system. The protein was eluted by a linear gradient of LanP buffer to Elution Buffer (20 mM HEPES, 1 M NaCl, 500 mM imidazole, 10% glycerol, pH 7.5) over 30 min. The purest fractions, as determined by 4–20% SDS–PAGE, were combined, concentrated to 1 mg/ml by Amicon Ultra Centrifugal Filters (30 kDa MWCO), and buffer exchanged into",10,app\data\tmp\ALD patent background + target paper.pdf,257
0ab666ee2944a437b089e887351f1b4b,"storage buffer (20mM HEPES, 300 mM KCl, 10% glycerol, pH 7.5) by PD-10 desalting column (GE Healthcare). Protein concentration was determined by absorbance at 280 nm.",10,app\data\tmp\ALD patent background + target paper.pdf,258
35118004da4a57172db4dc16f570e424,"For the purification of CylLL′′ and CylLS′′ peptides, the cell paste was thawed and resuspended in 50 ml of LanA Buffer B1 (6 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5). The cell suspension was lysed via sonication (2-s pulse on, 5-s pulse off, 7 min total pulse on time). The cell lysate was clarified by centrifugation at 13,000g for 45 min. The clarified cell lysate was filtered through a 0.45-μm centrifugal filter and applied via gravity flow to a pre-equili-",10,app\data\tmp\ALD patent background + target paper.pdf,259
f93772ba29495d4d54e799b2641a431d,"brated, 2 ml bed volume of His60 Ni Superflow Resin (Clonetech). After the lysate had been applied, the resin was washed with 15 ml of LanA Buffer B2 (4 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5). The resin was washed again with 15 ml of LanA Wash Buffer (20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove the guanidine HCl. The peptides were eluted with 10 ml of LanA elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.5). A 0.02 mg/ml final",10,app\data\tmp\ALD patent background + target paper.pdf,260
fa1e6a4377c1eb22fedbbe84716db02b,concentration of CylA (27–412) was added to the elution fraction and allowed to incubate at room temperature overnight to remove the leader peptide.,10,app\data\tmp\ALD patent background + target paper.pdf,261
f613c71a30229d413a816cd4e71c313a,"The digestion was quenched by adding 2% (v/v) final concentration of trifluoroacetic acid. The solution was centrifuged at 4,500g for 10 min and filtered through a 0.45-μm syringe filter (Thermo Scientific). The core peptides were purified by semi-preparative reverse-phase HPLC using a Phenomenex Jupiter Proteo column (10 mm × 250 mm, 4 μm, 90 Å) connected to an Agilent 1260 Infinity II liquid chromatography system. The peptides were separated using a linear gradient of 3% (v/v) solvent B",10,app\data\tmp\ALD patent background + target paper.pdf,262
48b6f380f80fde55031285a588b0b570,"(acetonitrile + 0.1% trifluoroacetic acid) in solvent A (water + 0.1% trif- luoroacetic acid). The fractions were spotted on a matrix-assisted laser desorption/ionization (MALDI) target plate by mixing 1 μl of sample with 1 μl of a 25 mg/ml solution of Super-DHB (Sigma) in 80% acetonitrile/water + 0.1% trifluoroacetic acid. The fractions were analysed by MALDI–time of flight (TOF) mass spectrometry on a Bruker UltrafleXtreme MALDI–TOF/ TOF operating in positive ionization, reflector mode.",10,app\data\tmp\ALD patent background + target paper.pdf,263
da1d120af23978f0fbae2d699a98fbb4,Primary mouse hepatocytes,10,app\data\tmp\ALD patent background + target paper.pdf,264
d6a505a150d5f1086f9532a19daabd71,Hepatocytes were isolated from C57BL/6 female mice fed the chronic– binge ethanol diet (NIAAA model)15. Livers were perfused in situ with 0.5 mM EGTA containing calcium-free salt solution and then perfused with a solution containing 0.02% (w/v) collagenase D (Roche Applied Science). Livers were then carefully minced and filtered using a 70-μm nylon cell strainer. Hepatocytes were centrifuged at 50g for 1 min after 3 washes. Hepatocyte viability was assessed by Trypan Blue (Thermo Fisher,10,app\data\tmp\ALD patent background + target paper.pdf,265
54fa47a2ab564d5daf7d4220d12371a6,"Scientific). Hepatocytes (1.5 × 105) were seeded on 12-well plates coated with rat collagen type I in DMEM-F12 (Thermo Fisher Scientific) with insulin–transferrin–selenium (1% v/v) (Thermo Fisher Scientific) and 40 ng/ml dexamethasone (MP Biomedicals) containing 10% (v/v) fetal bovine serum (FBS) (Gemini Bio-Products) and antibiotics. After 4 h, the culture was washed with DMEM-F12 medium and changed to the same complemented medium without FBS58. Then 16 h later, hepato- cytes were cultured with",10,app\data\tmp\ALD patent background + target paper.pdf,266
1372b306aa0c52d2c525b499046434c5,"0 or 25 mM ethanol and stimulated with 0, 200 or 400 nM CylLS′′ and/or CylLL′′ in the same culture medium without FBS. After 3 h stimulation, hepatocyte cytotoxicity was assessed using Pierce LDH cytotoxicity detection kit (Thermo Fisher Scientific).",10,app\data\tmp\ALD patent background + target paper.pdf,267
fd456c1fee76b1cb3ea26a7ef7210571,Biochemical analysis,10,app\data\tmp\ALD patent background + target paper.pdf,268
8a148d1dc09c307807cd802c25880837,Serum levels of ALT were determined using Infinity ALT kit (Thermo Scientific). Hepatic triglyceride levels were measured using Triglyceride,10,app\data\tmp\ALD patent background + target paper.pdf,269
0c4ab9ba58f8a9f0c516a53f313acf84,"Liquid Reagents kit (Pointe Scientific). Levels of serum lipopolysac- charide and faecal albumin were determined by enzyme-linked immu- nosorbent kits (Lifeome Biolabs and Bethyl Labs, respectively). Serum levels of ethanol were measured using ethanol assay kit (BioVision).",11,app\data\tmp\ALD patent background + target paper.pdf,270
797d8bf4a145612497ef177bd5a6239f,Staining procedures,11,app\data\tmp\ALD patent background + target paper.pdf,271
3dee410995fd19ff3eafb7fd0b587362,"Formalin-fixed tissue samples were embedded in paraffin and stained with H & E. To determine lipid accumulation, liver sections were embed- ded in OCT compound. Eight-micrometre frozen sections were then cut and stained with Oil Red O (Sigma-Aldrich). Representative images from each group of mice are shown in each figure. The terminal deoxynucleo- tide transferase-mediated dUTP nick-end labelling (TUNEL) assay was performed using an in situ cell death detection kit (Sigma-Aldrich). We randomly",11,app\data\tmp\ALD patent background + target paper.pdf,272
c6cd8a3349ba368e9bb88818984c8d7b,selected five high-power fields for counting TUNEL-positive cells and normalized numbers to total cells.,11,app\data\tmp\ALD patent background + target paper.pdf,273
6a42912441ca7866eabbfab334d60e72,Statistical analysis,11,app\data\tmp\ALD patent background + target paper.pdf,274
cdcbc2f2e23102ccf1a440852ed86eb5,"Results are expressed as mean ± s.e.m. (except when stated otherwise). Univariate and multivariate Cox regression analysis was used to detect associations of cytolysin with overall mortality. The multivariate model was adjusted for geographical origin of the patients, antibiotic treat- ment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. Univariate logistic regression analysis of laboratory and clinical parameters associated with the detection of cytolysin and",11,app\data\tmp\ALD patent background + target paper.pdf,275
150a4d5c57b757134ff513ecabb5f12c,"E. faecalis was performed. Univariate linear regression analysis of labo- ratory and clinical parameters associated with the log-transformed total amount of faecal E. faecalis measured with qPCR was performed. To associate log-transformed total E. faecalis and E. faecalis positiv- ity with mortality, univariate Cox regression was used. P values from univariate and multivariate Cox regression, univariate logistic regres- sion and univariate linear regression were determined by Wald test.",11,app\data\tmp\ALD patent background + target paper.pdf,276
fc109a1030828f1037288067fe4f95a5,"Multicollinearity was examined using the variance inflation factor. Kaplan–Meier curves were used to compare survival between cytolysin- positive and cytolysin-negative patients with alcoholic hepatitis. Faecal E. faecalis, bacterial diversity and richness from controls and patients were compared using Kruskal–Wallis test with Dunn’s post hoc test. Region- and/or centre-specific clinical characteristics of patients with alcoholic hepatitis were compared with Kruskal–Wallis test for continu- ous",11,app\data\tmp\ALD patent background + target paper.pdf,277
a19054635354e3e0e2ffcd77f0cdd614,"and Fisher’s exact test for categorical variables. Faecal E. faecalis in patients with alcoholic hepatitis with or without cytolysin, and with or without cirrhosis, were compared with Mann–Whitney-Wilcoxon rank-sum test. Faecal E. faecalis in patients with alcoholic hepatitis from different region and/or centres were compared with the Kruskal– Wallis test. The percentage of subjects with faecal samples that were positive for E. faecalis and cytolysin was compared using Fisher’s exact test,",11,app\data\tmp\ALD patent background + target paper.pdf,278
56a24649d0c7e297b56bea9606728bff,"followed by FDR procedures for multiple group comparisons. Jaccard dissimilarity matrices were used for PCoA, and P values were determined by PERMANOVA followed by FDR procedures to correct for multiple comparisons.",11,app\data\tmp\ALD patent background + target paper.pdf,279
1e550a02ff98e960d75874252e3eb4c3,"For mouse and cell culture studies, the significance of multiple groups was evaluated using one-way or two-way ANOVA with Tukey’s post hoc test. Fisher’s exact test was used in the analysis of liver E. faecalis and cytolysin with FDR correction for multiple comparisons. Kaplan–Meier curves were used to compare survival between experi- mental mouse groups. PCoA based on Jaccard dissimilarity matrices was performed between experimental mouse groups and the P values were determined by PERMANOVA",11,app\data\tmp\ALD patent background + target paper.pdf,280
f1da5283e440f6d0fa55e2d17389d60f,followed by FDR procedures to cor- rect for multiple comparisons.,11,app\data\tmp\ALD patent background + target paper.pdf,281
35dd258ac8e5ba5436716f4ce9fbd3c0,"Exact P values for all comparisons, together with group size for each group, were listed in Supplementary Table 10. Statistical analyses were performed using R statistical software, R v.3.5.1 (R Foundation for Sta- tistical Computing) and GraphPad Prism v.6.01. A value of P < 0.05 was considered to be statistically significant (adjusted for multiple comparisons when performing multiple tests).",11,app\data\tmp\ALD patent background + target paper.pdf,282
5e8e0d834444aa3c291716bd9f59b02a,Reporting summary,11,app\data\tmp\ALD patent background + target paper.pdf,283
d285f0d15500d175ba258c33a408d6b9,Further information on research design is available in the Nature Research Reporting Summary linked to this paper.,11,app\data\tmp\ALD patent background + target paper.pdf,284
95317ec5281cabb98f323340f5ac0649,Data availability,11,app\data\tmp\ALD patent background + target paper.pdf,285
a0ccd942e172e3dc2e0073be38eb7820,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSa- mple identifiers (SAMN11089809–SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at the ENA under study PRJEB25007.,11,app\data\tmp\ALD patent background + target paper.pdf,286
6b9e0454041476be11839d66d772e465,Code availability,11,app\data\tmp\ALD patent background + target paper.pdf,287
7fbe703180a78a923085bd8ee74f1204,The PERL script for making the genetic maps of phage genomes can be found at https://github.com/JCVenterInstitute/LinearDisplay.,11,app\data\tmp\ALD patent background + target paper.pdf,288
9a4490f7fdfcd9a2d5f3c31bbc4ea065,"30. Brandl, K. et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J. Hepatol. 69, 396–405 (2018).

31. Gao, B. et al. Serum and fecal oxylipins in patients with alcohol-related liver disease. Dig. Dis. Sci. 64, 1878–1892 (2019).

32. Lang, S. et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology (2019).",11,app\data\tmp\ALD patent background + target paper.pdf,289
0d07213baf05b731e04176045f314e01,"33. Ball, S. A., Tennen, H., Poling, J. C., Kranzler, H. R. & Rounsaville, B. J. Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers. J. Abnorm. Psychol. 106, 545–553 (1997).",11,app\data\tmp\ALD patent background + target paper.pdf,290
825e40d7c9863038d7132a717c96d453,"34. Krieg, L. et al. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood 118, 6418–6425 (2011).",11,app\data\tmp\ALD patent background + target paper.pdf,291
dfe55cd718ae3cd51285786e6b6cef3f,"35. Gill, J. J. et al. The Caulobacter crescentus phage phiCbK: genomics of a canonical phage. BMC Genomics 13, 542 (2012).

36. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Completing bacterial genome assemblies with multiplex MinION sequencing. Microb. Genom. 3, e000132 (2017).

37. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLOS Comput. Biol. 13, e1005595 (2017).",11,app\data\tmp\ALD patent background + target paper.pdf,292
40f7fcfe4e1ea3b02de481043241744d,"38. Walker, B. J. et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS ONE 9, e112963 (2014).",11,app\data\tmp\ALD patent background + target paper.pdf,293
c3ae41bc099848f53dd13ce483aee1e4,"39. Santiago-Rodriguez, T. M. et al. Transcriptome analysis of bacteriophage communities in periodontal health and disease. BMC Genomics 16, 549 (2015).

40. Haft, D. H. et al. RefSeq: an update on prokaryotic genome annotation and curation. Nucleic Acids Res. 46, D851–D860 (2018).

41. Tatusova, T. et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 44, 6614–6624 (2016).",11,app\data\tmp\ALD patent background + target paper.pdf,294
f22df2e91ee63873daeaeeb420f2c6d4,"42. Fouts, D. E. Phage_Finder: automated identification and classification of prophage regions in complete bacterial genome sequences. Nucleic Acids Res. 34, 5839–5851 (2006).",11,app\data\tmp\ALD patent background + target paper.pdf,295
a64db594ab20b3441a1dae4c8d6ceb61,"43. Ondov, B. D. et al. Mash: fast genome and metagenome distance estimation using MinHash. Genome Biol. 17, 132 (2016).",11,app\data\tmp\ALD patent background + target paper.pdf,296
018195dbaccc44785485100492266ba4,"44. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics 35, 526–528 (2019).

45. Letunic, I. & Bork, P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 44, W242–W245 (2016).",11,app\data\tmp\ALD patent background + target paper.pdf,297
3e0ba75764ec36ea6bc81ae92b78ca56,"46. Valentine, R. C., Shapiro, B. M. & Stadtman, E. R. Regulation of glutamine synthetase. XII. Electron microscopy of the enzyme from Escherichia coli. Biochemistry 7, 2143–2152 (1968).",11,app\data\tmp\ALD patent background + target paper.pdf,298
d519982cd34d5b1835e58cebe42431f6,"47. Haas, B. J. et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21, 494–504 (2011).

48. Caporaso, J. G. et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc. Natl Acad. Sci. USA 108 (Suppl 1), 4516–4522 (2011).",11,app\data\tmp\ALD patent background + target paper.pdf,299
3cbed6519cb2f120e5450e5e6c241a08,"49. Chen, P. et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148, 203–214.e16 (2015).",11,app\data\tmp\ALD patent background + target paper.pdf,300
1e107ef1fc4927aa2c4b50226bd5a989,"50. Ryu, H. et al. Development of quantitative PCR assays targeting the 16S rRNA genes of Enterococcus spp. and their application to the identification of enterococcus species in environmental samples. Appl. Environ. Microbiol. 79, 196–204 (2013).",11,app\data\tmp\ALD patent background + target paper.pdf,301
f83f50ca3718b2704abc86a8094565a4,"51. Haas, W., Shepard, B. D. & Gilmore, M. S. Two-component regulator of Enterococcus faecalis cytolysin responds to quorum-sensing autoinduction. Nature 415, 84–87 (2002).",11,app\data\tmp\ALD patent background + target paper.pdf,302
9586c1148cff7df64b922150b0cc9ab1,"52. Page, A. J. et al. Robust high-throughput prokaryote de novo assembly and improvement pipeline for Illumina data. Microb. Genom. 2, e000083 (2016).",11,app\data\tmp\ALD patent background + target paper.pdf,303
850611bfacd41e9295be00c4d7bf6562,"53. Chen, L. et al. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 33, D325–D328 (2005).

54. Jia, B. et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 45, D566–D573 (2017)",11,app\data\tmp\ALD patent background + target paper.pdf,304
c5cf8aaaa6e42e353700c44f62b51cca,"55. Seemann, T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 2068–2069 (2014).

56. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312–1313 (2014).",11,app\data\tmp\ALD patent background + target paper.pdf,305
6db78e24cbe8ce92a22b0bd3a1a2d4d3,Article,12,app\data\tmp\ALD patent background + target paper.pdf,306
d9d515a6c8418ccca4b59dd46fe52c5a,"57. Tang, W., Bobeica, S. C., Wang, L. & van der Donk, W. A. CylA is a sequence-specific protease involved in toxin biosynthesis. J. Ind. Microbiol. Biotechnol. 46, 537–549 (2019).",12,app\data\tmp\ALD patent background + target paper.pdf,307
1cfc057599f09fb013e9a3d470d757f4,"58. Iwaisako, K. et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc. Natl Acad. Sci. USA 109, E1369–E1376 (2012).",12,app\data\tmp\ALD patent background + target paper.pdf,308
cd1809eb4085675396581bd8d30742b3,"59. Clarke, T. H., Brinkac, L. M., Sutton, G. & Fouts, D. E. GGRaSP: a R-package for selecting representative genomes using Gaussian mixture models. Bioinformatics 34, 3032–3034 (2018).",12,app\data\tmp\ALD patent background + target paper.pdf,309
3ec2fd2519e97bded7adbeca1c9bfde9,"Acknowledgements S. Lang was supported by a DFG fellowship (LA 4286/1-1), C.L. was supported by an AASLD Pinnacle Research Award in Liver Disease and a pilot project award from Southern California Research Center for Alcoholic Liver and Pancreatic Disease (ALPD) and Cirrhosis (P50 AA011999), Y.S. was supported by a Wellcome Trust PhD studentship and I.R.R. was supported by National Institute of General Medical Sciences (NIGMS)–NIH Chemistry–Biology Interface Training Grant (T32-GM070421). This",12,app\data\tmp\ALD patent background + target paper.pdf,310
deccb1cc2cf3d51f4fef118882b0a3c7,"study was supported in part by a Biocodex Microbiota Foundation Grant, NIH grants R01 AA24726, U01 AA026939, by Award Number BX004594 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (to B.S.), the Wellcome Trust (WT098051) (to T.D.L.), NIH grant U01AA021908 (to R.B.) and services provided by P30 DK120515 and P50 AA011999.",12,app\data\tmp\ALD patent background + target paper.pdf,311
e7800e29e070518761d65d425cba99ac,"Author contributions Y.D. was responsible for acquisition, analysis and interpretation of data, and drafting of the manuscript; C.L. was responsible for study concept and design, acquisition,",12,app\data\tmp\ALD patent background + target paper.pdf,312
1f320dc31ff460b26e97cf0228120154,"analysis and interpretation of data and key preliminary experiments; S. Lang, K.B., J.L. and X.M.T. provided assistance with statistical analysis; H.C., L.J., B.G., W.S., R.K., F.H. and S. Lee provided assistance with data acquisition; R.C.W., T.H.C., K.N., M.T. and D.E.F. were responsible for 16S rRNA sequencing, phage genome sequencing and data analysis; Y.S. and T.D.L. were responsible for bacterial genome sequencing and data analysis; A.H.-M., L.L. and R.Y. provided assistance with phage",12,app\data\tmp\ALD patent background + target paper.pdf,313
40b69c515c1355716a1f51ae512bc792,"studies and were responsible for electron microscopy data; R.Y. provided critical revision of the manuscript; I.R.R. and W.A.v.d.D. were responsible for cytolysin expression and purification; Y.M. and L.E. provided assistance with the design and conduct of the gnotobiotic mouse studies; M.L. and D.P. provided assistance with phage isolation; M.V.-C., F.B.-P., E.C.V., J.G.A., R.S.B. Jr, V.V., J.A., J.C., D.L.S., S.B.H., A.L., M.R.L., P.M., G.G.-T., R.B. and P.S. were responsible for collection of",12,app\data\tmp\ALD patent background + target paper.pdf,314
6718f5eb0f7d9f8bd7ed60ccf4f01363,"human samples; D.E.F. and B.S. were responsible for the study concept and design, and editing the manuscript; B.S. was responsible for study supervision.",12,app\data\tmp\ALD patent background + target paper.pdf,315
1b2cb9cd242fdba3cede9423f0ac2ee9,"Competing interests B.S. consults for the Ferring Research Institute; however, there is no competing interest with regard to this study. All other authors declare no competing interests.",12,app\data\tmp\ALD patent background + target paper.pdf,316
42a7f898bf6ec8b37c7a99bc5bd9f4c8,Additional information,12,app\data\tmp\ALD patent background + target paper.pdf,317
42016602a8de363092ebaf834d6d8b5b,Supplementary information is available for this paper at https://doi.org/10.1038/s41586-019- 1742-x.,12,app\data\tmp\ALD patent background + target paper.pdf,318
bd5f1a86e9f4a636255b397e71dd1fe6,Correspondence and requests for materials should be addressed to B.S.,12,app\data\tmp\ALD patent background + target paper.pdf,319
9a00d9a5bcf52ab55dac0a1ce0f81078,Reprints and permissions information is available at http://www.nature.com/reprints.,12,app\data\tmp\ALD patent background + target paper.pdf,320
bf88174fdc5a56d6ce497ae968eac4a5,1Y) - 8 Bacterial Genera Bacteroides o Unclassified Ruminococcaceae ®© © o Unclassified Lachnospiraceae Akkermansia Veellionella 3 Prevotella Blautia 3 Escherichia/Shigella Rosebuna g Streptococcus Unclassified Clostndiales Dialister & Faecalibacterium Ruminococcus Clostndium_XiVa 8 Enterococcus S Megasphaera Ruminococcus2 S Megamonas Relative sequence abundance (%) L B=R-R-N=) B=R-§ B=N N=§ N-§ Bo) N-Q B N | Bifidobacterium ... [remaining 309 | o | Alcoholic Controls AUD hepatitis,13,app\data\tmp\ALD patent background + target paper.pdf,321
3e9327712f8c196c0f356348d344eb94,o k% % % = N Shannon diversity Controls Alcoholic AUD hepatitis,13,app\data\tmp\ALD patent background + target paper.pdf,322
1baed7bc518d0efbd3f1a0e59d059a0f,Simpson diversity,13,app\data\tmp\ALD patent background + target paper.pdf,323
e01ab1a6370cd261d4a1eadf25241796,1.0,13,app\data\tmp\ALD patent background + target paper.pdf,324
6fa7a7d4e4ef2312b1f46bfd7c8e75ff,%,13,app\data\tmp\ALD patent background + target paper.pdf,325
2655a53adcebbd5597c79a7c87b27e58,"(=] o

o H

o N",13,app\data\tmp\ALD patent background + target paper.pdf,326
8cb850b414be0f013c2d55cf28a198bf,Controls,13,app\data\tmp\ALD patent background + target paper.pdf,327
3350bbee36dcc98a731f666af556d0fb,ko k.,13,app\data\tmp\ALD patent background + target paper.pdf,328
c63baa67683df37381bd2584b5da4844,AUD,13,app\data\tmp\ALD patent background + target paper.pdf,329
fda31d8f41332d038dafbae20925f533,ok,13,app\data\tmp\ALD patent background + target paper.pdf,330
a6ff599d2697fd421b63ef42108cb352,Alcoholic hepatitis,13,app\data\tmp\ALD patent background + target paper.pdf,331
4626b043628108f1925755f18874672d,Chao richness,13,app\data\tmp\ALD patent background + target paper.pdf,332
978970f2a179bfb33d227731299c915f,"10,000",13,app\data\tmp\ALD patent background + target paper.pdf,333
7addaac4944fb40f37e272a115d220c3,|,13,app\data\tmp\ALD patent background + target paper.pdf,334
977d8c31683f59801e19320d43fa72c8,"8,000

4,000

3,000

2,000

1,000",13,app\data\tmp\ALD patent background + target paper.pdf,335
76a4f054beb3fb06b8e8120a2b4da95d,0,13,app\data\tmp\ALD patent background + target paper.pdf,336
9c078452ab489dc4f7c4f98a8e0e663b,Controls,13,app\data\tmp\ALD patent background + target paper.pdf,337
fa44f7f27da1ad7fe56325613fcc72b7,ek ke,13,app\data\tmp\ALD patent background + target paper.pdf,338
d339cc44bf74425e94fb835dbd8c4271,AUD,13,app\data\tmp\ALD patent background + target paper.pdf,339
239a8215e4ce0146b3b0c6991d8038bc,g,13,app\data\tmp\ALD patent background + target paper.pdf,340
c8d5d152b31d10141d69a05cac396ef7,Alcoholic hepatitis,13,app\data\tmp\ALD patent background + target paper.pdf,341
d7a2ec4ec89620b7a34fa301f380ac51,"(1] 5 o © o (=] o » -Cytolysin, AUC=0.81 Sensitivity -MELD, AUC=0.70 Y -ABIC, AUC=0.66 -DF, AUC=0.63 S 0.0 0.2 0.4 0.6 0.8 1.0 1 - Specificity",13,app\data\tmp\ALD patent background + target paper.pdf,342
f9f445ee01ed77606333bcd96991e96e,"Enterococcus faecalis e % % K 150,000 e e 100,000 50,000 . 300 T Fraeseeant 300 Relative abundance 100 I | etaes - 100 ""u, e Controls Alcoholic AUD hepatitis

@@ E. faecalis negative 3 E. faecalis positive 100 80 60 40 20 Percent subjects (%) Controls AUD Alcoholic hepatitis",13,app\data\tmp\ALD patent background + target paper.pdf,343
60640fb418a92205c3f105927181635c,@@,13,app\data\tmp\ALD patent background + target paper.pdf,344
e35a3a81523b0652eb144cb379d3369c,3,13,app\data\tmp\ALD patent background + target paper.pdf,345
d62c8d36fa95c44e77c1132c4fbf694d,"0.50 France Mexico 0.25 Spain g UK PC2 (16.74%) y USA East USA Midwest ; 9 USA West m[mn[m|n[n]m -0.4 0.4 PC1 (()iﬂ A7%)

@@ E. faecalis negative 3 E. faecalis positive 100 80 60 40 20 Percent subjects (%) 0 & Q9 P i o Q/’b & & & ?""‘;\6 &",13,app\data\tmp\ALD patent background + target paper.pdf,346
6d51c0fc6146bab7783b6062ec741a42,@@,13,app\data\tmp\ALD patent background + target paper.pdf,347
e260f5223a829da66eb43a9c429f2f0a,3,13,app\data\tmp\ALD patent background + target paper.pdf,348
eb8fb859c35a49e88b6b484618aa3ddf,Bl Cytolysin negative Em Cytolysin positive 100 80 60 40 20 Percent subjects (%) Cirrhosis Non- cirrhosis,13,app\data\tmp\ALD patent background + target paper.pdf,349
ff98ced0129be9d98b6055bfddfb3a98,Bl,13,app\data\tmp\ALD patent background + target paper.pdf,350
d3399b457e6f2dfd30c893815181e247,Em,13,app\data\tmp\ALD patent background + target paper.pdf,351
be0868751b0169fe0a131584457feb2b,Extended Data Fig. 1 | See next page for caption.,13,app\data\tmp\ALD patent background + target paper.pdf,352
303d327a6822bc312650408c47fc0072,"Enterococcus faecalis 150,000 100,000 - 50,000 - —t— — Relative abundance 1,000 1,oogI| e | Lo ] Cytolysin Cytolysin negative positive

Enterococcus faecalis 150,000 100,000 50,000 - Relative abundance 1oﬁi.n_|.|-ii-é o 1gI|,.| oLl ] Lo & S Q,’b 4‘0 « & $+ & F X ¥

@@ E. faecalis negative 3 E. faecalis positive 100 80 60 40 20 Percent subjects (%) Cirrhosis Non- cirrhosis",13,app\data\tmp\ALD patent background + target paper.pdf,353
4874b79024d05d7e09f5ae0ff9437db8,@@,13,app\data\tmp\ALD patent background + target paper.pdf,354
799990050eb7af76b71b628a695d69cb,3,13,app\data\tmp\ALD patent background + target paper.pdf,355
1b29f11f1da46136e0074dfce5fc59c9,Em Cytolysin negative Bl Cytolysin positive = [~ o [=2] o H o [ o Percent subjects (%) Y & & oy & <« ¢&+ & Nl 28 &,13,app\data\tmp\ALD patent background + target paper.pdf,356
ab9d761d7498020d9e3af2a202778cec,Em,13,app\data\tmp\ALD patent background + target paper.pdf,357
5f6f2b3830720225ff9798cc8f11da9d,Bl,13,app\data\tmp\ALD patent background + target paper.pdf,358
6dd8bbfdc1ad608af885b26e958c45af,Enterococcus faecalis,13,app\data\tmp\ALD patent background + target paper.pdf,359
cff7e8994b42ff6d975f6fdc848181c1,"80,000",13,app\data\tmp\ALD patent background + target paper.pdf,360
4333362ade57e20fe457e432a889bc35,Relative abundance,13,app\data\tmp\ALD patent background + target paper.pdf,361
e0ebd00e326064337c43631660861f54,"60,000

40,000

20,000",13,app\data\tmp\ALD patent background + target paper.pdf,362
25f645fc0af96022106617307c8b9c95,PR U F— ) I O N o,13,app\data\tmp\ALD patent background + target paper.pdf,363
c24b9f3c02622c94c69d2f251e2401e8,i 0,13,app\data\tmp\ALD patent background + target paper.pdf,364
2649be59c19e83281ae2572c4f58c469,"Cirrhosis

Non- cirrhosis",13,app\data\tmp\ALD patent background + target paper.pdf,365
5b4657ccb3732f4e5c5ef7bba255e78e,Article,14,app\data\tmp\ALD patent background + target paper.pdf,366
bb5f6015b28098305d709846d456b5e7,"Extended Data Fig. 1 | Intestinal dysbiosis in patients with alcoholic hepatitis. a, 16S rRNA sequencing of faecal samples from controls (n = 14), patients with alcohol-use disorder (n = 43), or alcoholic hepatitis (n = 75). The graph demonstrates the relative abundance of sequence reads in each genus. b, Bacterial diversity (Shannon index and Simpson index) and richness (Chao richness) was calculated in controls (n = 14), patients with alcohol-use disorder (n = 43) or alcoholic hepatitis (n =",14,app\data\tmp\ALD patent background + target paper.pdf,367
a1324180374f2aafb4027c0015e8fa9c,"75). c, E. faecalis in faecal samples from controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. d, Percentage of faecal samples positive for E. faecalis in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. E. faecalis was detected in faeces from 80% of patients with alcoholic hepatitis, versus 36% of controls (P < 0.001). There was also a significant difference between",14,app\data\tmp\ALD patent background + target paper.pdf,368
812a8de9714a76c2996d8cadf9212ddd,"patients with alcohol-use disorder and patients with alcoholic hepatitis (P < 0.01). e, Receiver operating characteristic curves and area under the curve (AUC) for the comparison of 90-day mortality and cytolysin positivity (red; n = 57), MELD score (blue; n = 56), ABIC score (yellow; n = 57) and discriminant function (green; n = 42) in patients with alcoholic hepatitis. f, E. faecalis in faecal samples from patients with alcoholic hepatitis whose faecal samples were cytolysin- positive (n = 25)",14,app\data\tmp\ALD patent background + target paper.pdf,369
ea93f5e0d9ffae6be16da80230e78ad6,"or cytolysin-negative (n = 54), assessed by qPCR (P = 0.8174). g, 16S rRNA sequencing of faecal samples from patients with alcoholic hepatitis from different centres (France, n = 9; Mexico, n = 6; Spain, n = 5; UK, n = 11; USA (east), n = 16; USA (Midwest), n = 12; USA (west), n = 16 patients). We used PCoA based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between patients from different",14,app\data\tmp\ALD patent background + target paper.pdf,370
5d069ec59e7df60dd37bcc5849d2f946,"regions (P < 0.01). h, Percentage of faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin- positive), in patients with alcoholic hepatitis from different centres (France,",14,app\data\tmp\ALD patent background + target paper.pdf,371
38fc8bc69e98ee96d43dfae226c9577a,"n = 16; Mexico, n = 6; Spain, n = 6; UK, n = 10; USA (east), n = 16; USA (Midwest), n = 13; USA (west), n = 15 patients), assessed by qPCR (P = 0.6094). i, E. faecalis in faecal samples from patients with alcoholic hepatitis from different centres, assessed by qPCR (P = 0.5648). j, Percentage of faecal samples that were positive for E. faecalis in patients with alcoholic hepatitis from different centres (France, n = 16; Mexico, n = 6; Spain, n = 6; UK, n = 10; USA (east), n = 16; USA (Midwest),",14,app\data\tmp\ALD patent background + target paper.pdf,372
15b4c32b2e084db7003b5530e36c6cc4,"n = 13; USA (west), n = 15 patients), assessed by qPCR (P = 0.0529). k, Percentage of subjects with faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin-positive), in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.3431). l, E. faecalis in faecal samples from patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.5736). m, Percentage of faecal samples that were",14,app\data\tmp\ALD patent background + target paper.pdf,373
4c0a08a44b51738324c3eb908a23de13,"positive for E. faecalis in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.2878). Results are expressed as mean ± s.e.m. (c, f, i, l). For the box and whisker plots in b, the box extends from the 25th to 75th percentiles, and the centre line represents the median; for all three groups, the bottom whiskers show the minimum values; for the control group (black), the top whisker shows the maximum value; for the other two groups, the top",14,app\data\tmp\ALD patent background + target paper.pdf,374
499b730b08a2361a323d32f0ae34619f,"whiskers represent the 75th percentile plus 1.5× the inter-quartile distance (the distance between the 25th and 75th percentiles); all values greater than this are plotted as individual dots. P values were determined by Kruskal– Wallis test (i) with Dunn’s post hoc test (b, c), two-sided Fisher’s exact test (h, j, k, m) followed by FDR procedures (d), two-sided Mann–Whitney Wilcoxon rank-sum test (f, l) or PERMANOVA (g). The exact group size (n) and P values for each comparison are listed in",14,app\data\tmp\ALD patent background + target paper.pdf,375
f06ff377e3a027fc986424b60aa15b4c,"Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",14,app\data\tmp\ALD patent background + target paper.pdf,376
0ad40e6e8506f67f89f8ee6037594927,"Serum ALT 400 ok 300 200 é{ i 100 o1 E=A [od oq Control Ethanol

b un Fold change oo H Fod Control Ethanol",15,app\data\tmp\ALD patent background + target paper.pdf,377
a5323d0e0ff1b3188dc221b46ec66bcc,«,15,app\data\tmp\ALD patent background + target paper.pdf,378
ebed48ed62ccabe5374f0e7d8db6450a,« =~ E. faecalis Acytolysin —— E. faecalis 100 920 80 70 Log-rank test 60 (Mantel-Cox) Percent survival (%) P<0.05 50 10 Days,15,app\data\tmp\ALD patent background + target paper.pdf,379
e0da8db9f9e9670a1e40c0220775f9ef,"=~

——",15,app\data\tmp\ALD patent background + target paper.pdf,380
acd8e33567a67f0e6d212de584d07f76,"Fecal albumin

Fecal albumin 400 ExKK 30 - .l ~n ) 200 %g 10 [ [aa] il} Control Ethanol",15,app\data\tmp\ALD patent background + target paper.pdf,381
8870b1c32b3afea5779b69e9968aa16e,"Serum ethanol 1,000 [T} 800 ] u S 600 Eggm —— 400 200 Ethanol",15,app\data\tmp\ALD patent background + target paper.pdf,382
9ee01288146687d33c9f75ccaa8d98fb,Extended Data Fig. 2 | See next page for caption.,15,app\data\tmp\ALD patent background + target paper.pdf,383
4e9a4ffb9a0472155f6ac67707791a62,") G y Control - 30 #2Y Ethanol PBS E. faecalis E. faecalis Acytolysin

Hepatic triglycerides H PBS 40 W E. faecalis Sun "" B E. faecalis Acytolysin 30 L 20 E; 10 oo [ =] i i Control Ethanol",15,app\data\tmp\ALD patent background + target paper.pdf,384
3679e568a6aa502408f1e5a284737787,"Cxcl1 — "" Fold change u oo o e 185 [ o Control Ethanol",15,app\data\tmp\ALD patent background + target paper.pdf,385
86f7664c1ed7c3de98a581e60ef07af6,"Liver cylLg 100 Sk Jkk .5 ok, 80 60 40 Percent mice (%) 20 nd nd nd Control Ethanol

Serum LPS 60 Jkk —— 40 L [N (ng/ml) 20 Qo il 27 [on] Control Ethanol

Adht & S . P oo 1] : 5 Fold change o i g S Control Ethanol

Cxcl2 kx| 10 (L] Fold change [nal G Control Ethanol",15,app\data\tmp\ALD patent background + target paper.pdf,386
9b2d329773b2d3ba4523e3d6b6cd6cf4,"Liver E. faecalis 100 © (= a (= S (= Percent mice (%) n (= nd = Control Ethanol

Liver Enterococcus",15,app\data\tmp\ALD patent background + target paper.pdf,387
5a63c0234c4414840b38f9d73ae13189,"1,500",15,app\data\tmp\ALD patent background + target paper.pdf,388
a9d00cfa6b86308f58056ac3b6ac1d32,LL],15,app\data\tmp\ALD patent background + target paper.pdf,389
fa95f4d1e17cd8743ca43347cd529911,"1,000",15,app\data\tmp\ALD patent background + target paper.pdf,390
733f3b8b417608ff5e9615c763a7dae9,é?,15,app\data\tmp\ALD patent background + target paper.pdf,391
9e87040741a76c4fd1124601545a3fd8,500,15,app\data\tmp\ALD patent background + target paper.pdf,392
db8e90ffa870eab1ffb077819435b373,"Ethanol

0.50 PBS E. faecalis Control 0.25 ' E. faecalis Acytolysin .‘ PBS B E. faecalis Ethanol 0.00 g% ‘& B E. faecalis Acytolysin -0.25: -0.4 0.4 PC1 (:97.64%)

Cyp2e1 25 2.0 - o "" ;- - (= Fold change b 1F 0.0 Control Ethanol",15,app\data\tmp\ALD patent background + target paper.pdf,393
6e0c4d4b2927288bbd121a2264e7dfb6,Fecal Enterococcus 1010 108 2109 104 102 24 48 72 Time (hrs),15,app\data\tmp\ALD patent background + target paper.pdf,394
3a82518ceeed37cd373c6061536c697c,Article,16,app\data\tmp\ALD patent background + target paper.pdf,395
7ac46c5af68b1800934ae74353cc3ac0,"Extended Data Fig. 2 | Cytolytic E. faecalis causes the progression of ethanol-induced liver disease in mice. a–n, C57BL/6 mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with vehicle (PBS), a cytolytic E. faecalis strain (FA2-2(pAM714)) (denoted E. faecalis) (5 × 108 CFUs) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5 (denoted E. faecalis Δcytolysin) (5 × 108 CFUs) every third day. a, Serum levels of ALT. b, Hepatic triglyceride content. c,",16,app\data\tmp\ALD patent background + target paper.pdf,396
84d59088067a87182bb5a04ccf6bb4ff,"Representative oil red O-stained liver sections. d–f, Hepatic levels of mRNAs. g, Kaplan–Meier curve of survival of mice on chronic–binge ethanol diets (day 0 denotes the start of ethanol feeding). Mice gavaged with PBS all survived, and are not included in the figure. A higher proportion of mice (n = 15) gavaged with non-cytolytic E. faecalis survived than did mice (n = 25) gavaged with cytolytic E. faecalis. h, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR",16,app\data\tmp\ALD patent background + target paper.pdf,397
d6fa2830e925aad2cca000b0efebc1bf,"for cylLS (the gene that encodes cytolysin subunit CylLS′′). i, Proportions of mice that were positive for E. faecalis in the liver, measured by qPCR. About 80% of mice colonized with cytolytic E. faecalis, as well as those colonized with non- cytolytic E. faecalis, were positive for E. faecalis in their livers. j, Liver CFUs of Enterococcus in mice on a chronic–binge ethanol diet. k, Paracellular intestinal permeability was evaluated by measuring faecal albumin content and serum levels of",16,app\data\tmp\ALD patent background + target paper.pdf,398
c75eeeeff100eff17c41b8d19092d7b5,"lipopolysaccharide (LPS) by enzyme-linked immunosorbent assays. l, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices showed no significant differences among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis following",16,app\data\tmp\ALD patent background + target paper.pdf,399
a2c4c67e0961832c1ed0dab5e0524bb2,"feeding with the control and ethanol diets. Compared to mice fed with a control diet, mice fed with an ethanol diet had significantly different faecal microbiomes after gavaging with E. faecalis (P < 0.05). m, n, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis after ethanol feeding. o, Mice were gavaged with cytolytic or non- cytolytic E. faecalis strains (carrying the",16,app\data\tmp\ALD patent background + target paper.pdf,400
dad545b6e3f001f39c04d4e018a51445,"erythromycin resistance gene; 5 × 108 CFUs) at time 0, and faeces were collected 0, 8, 24, 48 and 72 h later. Faecal CFUs of Enterococcus were determined by culturing faecal samples on BBL enterococcosel broth agar plate with 50 μg ml-1 erythromycin. At time 0 and 72 h, five out of five and four out of five mice, respectively, had no detectable erythromycin-resistant Enterococcus in their faeces. These points are not shown on the graph, but have been included in the calculation of mean ± s.e.m.",16,app\data\tmp\ALD patent background + target paper.pdf,401
4fe82aa92993cb101a188a8c6ff93f55,"Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, j, k, m–o). P values among groups of mice fed with the control or ethanol diet were determined by one-way ANOVA with Tukey’s post hoc test (a, b, d–f, j, k, m, n), two-sided log-rank (Mantel–Cox) test (g), two-sided Fisher’s exact test followed by FDR procedures (h, i) or PERMANOVA followed by FDR procedures (l). All results were generated from at least three independent replicates. The exact group size (n) and P values for",16,app\data\tmp\ALD patent background + target paper.pdf,402
7c8ebf4e563c11ff6102d9cfbf7dae5c,"each comparison are listed in Supplementary Table 10. P values between mice fed with a control diet and mice fed with an ethanol diet were determined by two-way ANOVA (k). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",16,app\data\tmp\ALD patent background + target paper.pdf,403
5da72966955d9119b56ce686cf8735ab,"TUNEL £ AH cytolysin positive #1 rf AH cytolysin positive #2 AH cytolysin negative #3 [N AH cytolysin negative #4 Percent positive (%) i il uli 1l Control Ethanol

i o R Control . 3 /3% ¥ i Ethanol F IR “‘, o Ve, R | AH cytolysin AH cytolysin AH cytolysin AH cytolysin positive #1 positive #2 negative #3 negative #4

Cxcl2 s s :: Fold change - o oo 3 i g Control Ethanol

Acta2 10 Fold change Control Ethanol",17,app\data\tmp\ALD patent background + target paper.pdf,404
d07063272d38346ff35343d4a3a45f73,"- AH Cytolysin negative — AH Cytolysin positive "" 00 90; 80; 70 Log-rank test 60; (Mantel-Cox) Percent survival (%) P<0.05 50 2 oo 10 Days",17,app\data\tmp\ALD patent background + target paper.pdf,405
4688a707d682ec52ae8a704798448a4f,—,17,app\data\tmp\ALD patent background + target paper.pdf,406
702825aa6aeeca36694020824394ef6a,] AH cytolysin positive #1 g ] AH cytolysin positive #2 Control | AH cytolysin negative #3 ] AH cytolysin negative #4 H PC2 (24.13%) & 05 Pc1“('gz.44-/.,17,app\data\tmp\ALD patent background + target paper.pdf,407
a2a7c405087d276f5ceaeb86a11241a6,"]

]

|

]",17,app\data\tmp\ALD patent background + target paper.pdf,408
e0a50e089ee83f9d619413237350b497,"0.4- AH cytolysin pos ive #1 AH cytolysin posi #2 I Ethanol AH cytolysin negative #3 s AH cytolysin negative #4 g [m|m|m|m i PC2 (22.82%) 1 A S | | y/ y 0.4 02 0. OBet (65'1B%)

Cytolysin positive E. faecalis a 8 3 2 8 8 Percent colonies (%) nd nd o Patient Patient Patient Patient #1 # #3 # AH ¢y lysin AH cytolysin po: negative",17,app\data\tmp\ALD patent background + target paper.pdf,409
fbb1f0d8bdfc1538f8b6b90770016d54,"Serum ethanol 1,000 800 600 o % 400 - 200 Ethanol",17,app\data\tmp\ALD patent background + target paper.pdf,410
358ca365482a3fb97ab3f905a8b560ce,"Extended Data Fig. 3 | Transplantation of cytolysin-positive faeces increases ethanol-induced liver disease in gnotobiotic mice. a–f, h, i, C57BL/6 germ- free mice were colonized with faeces from two cytolysin-positive and two cytolysin-negative patients with alcoholic hepatitis, and then fed isocaloric (control) or chronic–binge ethanol diets. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the",17,app\data\tmp\ALD patent background + target paper.pdf,411
480d2679f746c9fc4f49dfd9d132fbe8,"inflammatory cytokine Cxcl2 and Acta2 (a marker of activated hepatic stellate cells). e, Kaplan–Meier curve of survival of mice on chronic–binge ethanol diets (day 0 denotes the start of ethanol feeding), gavaged with faeces from cytolysin-positive (n = 48 mice) or cytolysin-negative (n = 32 mice) patients with alcoholic hepatitis. f, Faecal samples were collected and 16S rRNA genes were sequenced. The graph shows PCoA of faecal microbiomes. No significant difference was observed between mice",17,app\data\tmp\ALD patent background + target paper.pdf,412
fae253ab8094bad5a8d9707023408fdb,"colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, following the control diet. Mice transplanted with faeces from a cytolysin-positive patient with alcoholic hepatitis (patient",17,app\data\tmp\ALD patent background + target paper.pdf,413
bc2aabf5f65a9fe5b4676aed02a7f7b8,Adh1 Cyp2et 2.5 2.0 2.0 - 1.5 o 15 e o - % . 1.0{ H - 1.0 H | Fold change Fold change 0.5: = W 0.5: 0.0 il 0.0 Control Ethanol Control Ethanol,17,app\data\tmp\ALD patent background + target paper.pdf,414
0672a270666c179071dfc2b9ee312f9d,"no. 2) showed a microbiota that was significantly different to that of the other mouse groups following ethanol administration (P < 0.01). g, Percentage of cytolysin-positive E. faecalis in four patients with alcoholic hepatitis. Stool samples from the four patients were placed on plates with selective medium, and Enterococcus colonies were identified by the production of a dark brown or black colour. Enterococcus colonies were confirmed to be E. faecalis by qPCR. The cytolysin status of each E.",17,app\data\tmp\ALD patent background + target paper.pdf,415
4cfb2ff98620b85c7ca831c8ffde664d,"faecalis colony was determined by qPCR. h, Serum levels of ethanol were comparable among colonized mice after ethanol feeding. i, Hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice on control or ethanol diets. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, h, i). P values were determined by one-way ANOVA with Tukey’s post hoc test (a, c, d, h, i), two- sided log-rank (Mantel–Cox) test (e) or PERMANOVA followed by FDR procedures (f). All",17,app\data\tmp\ALD patent background + target paper.pdf,416
40e59fb3efeded909c5e5da8e5bba1f6,"results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001.",17,app\data\tmp\ALD patent background + target paper.pdf,417
5a76823405eda647971b38b1d6e94dcf,Article,18,app\data\tmp\ALD patent background + target paper.pdf,418
0614e3479f45822e0de314c803aa31a4,"a > Head s v % | . 2 | % 5 oS .... Tail EZ%,//, Siphophage Myophage Podophage (long, flexible, (contractile tail) (short, noncontractile tail) noncontractile tail) S35 e ror ¥ 3 @ P T ¥ e % Efmus1 Efmus2 Efmus3 Efm us4 Efmus1 (17,927 bp) Iy b Efmus2 (18,366 bp) e Efmus3 (18,286 bp) YTy TSNy Efmus4 (18,186 bp) D b ool |:| encapsidation/terminase [ tail fiber [ DNA polymerase | [l endolysin/lysin | Il hypothetical protein - major capsid [ tail components [ DNA binding [ intron/intein [ holin Il",18,app\data\tmp\ALD patent background + target paper.pdf,419
2818e3cb929d83630bf1f72fe8355e76,vortal,18,app\data\tmp\ALD patent background + target paper.pdf,420
76f3c130435546d7b432ffa4ef948dd7,"Head

Tail",18,app\data\tmp\ALD patent background + target paper.pdf,421
d18d3b687e7e8fa84b924607d7aace60,major capsid,18,app\data\tmp\ALD patent background + target paper.pdf,422
7c746af7f41b98d88700069259edd802,"[

[

[

[",18,app\data\tmp\ALD patent background + target paper.pdf,423
46d0ab1bbfd577b7fb6579aa1e7762c2,Il,18,app\data\tmp\ALD patent background + target paper.pdf,424
bcf350b23e65e4c8b074eecd7322717e,vortal,18,app\data\tmp\ALD patent background + target paper.pdf,425
3b2c9474ba2c2b8caf35181873b66952,"Extended Data Fig. 4 | Isolation and amplification of phages against cytolytic E. faecalis isolated from mice. a, BHI agar plate showing phage plaque morphology. The phage cocktail (100 μl) (102–103 PFUs) was mixed with overnight-grown E. faecalis culture (100 μl) and then added to BHI broth top agar (0.5% agar) and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, images were captured on an Epson Perfection 4990 Photo scanner. b, Simplified illustration of the morphologies",18,app\data\tmp\ALD patent background + target paper.pdf,426
6124aa79b148b6a30cf469f16a75eb47,"of different phages. Siphophages have long, flexible noncontractile tails (left); myophages have contractile tails",18,app\data\tmp\ALD patent background + target paper.pdf,427
2d62d2fcc8d3f9914b213a28a3529761,"(middle); and podophages have short noncontractile tails (right). c, Transmission electron microscopy revealed that phages we isolated were all podophages (Efmus1, Efmus2, Efmus3 and Efmus4). d, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional role categories.",18,app\data\tmp\ALD patent background + target paper.pdf,428
38c083ce09b5170446d98c36d4d64a7f,"Scale bar, 50 nm. All results were generated from at least three independent replicates.",18,app\data\tmp\ALD patent background + target paper.pdf,429
597844106fb75bd02f95660618b05cee,"Serum ALT 500 — B 400 ~300 =200 - 5 100 ll' WT AMSI/SI WT Atp4a’s! Control Ethanol

Hepatic triglycerides PBS C. crescentus phages 60 E. faecalis phages PBS C. crescentus phages E EEEEEDN E. faecalis phages :'. i i WT AMES‘/S' WT MSI/SI Control Ethanol

St =y ) o 5 '!\.,a Control "" e | ey e ‘3 - L 3 Ethanol > R ] - I o 2 - e PBS C. crescentus phages E. faecalis phages PBS C. crescentus phages E. faecalis phages WT Atp4asis!",19,app\data\tmp\ALD patent background + target paper.pdf,430
24b8ea7f710aa06463fffe770ecb403a,"Cxcl1 15 frees e — e, 10 .- ""~ Fold change : - ok M | i WT AMSVS' WT AMSI/SI Control Ethanol

Cxcl2 poes 3 — i - o - =3 Fold change 2] . s H - H_| B L & WT AMSI/SI WT AMSVSI Control Ethanol

Liver cylLg 100 — s i 8 3 ] Percent mice (%) 8 2 nd o 3 AMSI/SI WT AMSI/SI Control Ethanol

b S — e - o - o Fold change ! 5 SUs! WT Atpda wWT Atp4as’/s' Control Ethanol

Fecal Enterococcus 1010 10° 2108 108 10% il | 104 WT Am‘asl/sl WT AMSI/SI Control Ethanol",19,app\data\tmp\ALD patent background + target paper.pdf,431
540d91ddf717a31b1d6694dfe3eaedfe,e PBS a C. crescentus phages o8 E. faecalis phages o o &q > Control PBS (10.08%) 5] C. crescentus phages Atpdastsi PC2 s E. faecalis phages -1.0 4 PC10(‘7)8.91%) 0,19,app\data\tmp\ALD patent background + target paper.pdf,432
5700e5f86ce623354b38dce66fc8d054,N,19,app\data\tmp\ALD patent background + target paper.pdf,433
c0a882eb3670d41034e821be9210d53a,Serum ethanol,19,app\data\tmp\ALD patent background + target paper.pdf,434
f47f6487e157d64c7b0cd56351ba2851,Adh1,19,app\data\tmp\ALD patent background + target paper.pdf,435
989912915db2a89f31fad259550ec0df,800,19,app\data\tmp\ALD patent background + target paper.pdf,436
bc36e2c5015fb535f4a1eaf9a7ae2867,%,19,app\data\tmp\ALD patent background + target paper.pdf,437
0836f71dadea3569fdeab2eb80087248,"600

400",19,app\data\tmp\ALD patent background + target paper.pdf,438
8e90ae85fc12cebe84b3c9584cab10c3,20,19,app\data\tmp\ALD patent background + target paper.pdf,439
6e73779162253e5d33d1607734519205,- o S il i,19,app\data\tmp\ALD patent background + target paper.pdf,440
fe82c49bcbda1fce20c998d36f5ebbbe,WT,19,app\data\tmp\ALD patent background + target paper.pdf,441
2ba599bb3cf35b824035c927d902d858,AMSI/SI,19,app\data\tmp\ALD patent background + target paper.pdf,442
1b019b96f6c83ecc2fbc4fa3b9069922,Fold change,19,app\data\tmp\ALD patent background + target paper.pdf,443
97cbd3c5e95b0a6645b8879b810ebaf7,H,19,app\data\tmp\ALD patent background + target paper.pdf,444
8aadd4be0c8070f7f26b98747eac0d5f,I I | AMSI/SI,19,app\data\tmp\ALD patent background + target paper.pdf,445
de5d318a50b9c81ee264395320ee592e,WT,19,app\data\tmp\ALD patent background + target paper.pdf,446
b7e174bda1afb8bb2275207f6d70de5d,"n,",19,app\data\tmp\ALD patent background + target paper.pdf,447
8cb35cc8392e2ab0eec5864df3167a8b,WT,19,app\data\tmp\ALD patent background + target paper.pdf,448
940913bc7d87557127a44ad9aa36a520,"E

:",19,app\data\tmp\ALD patent background + target paper.pdf,449
666baab980e9bc37303f2aebdebe7ed0,Awsa/s:,19,app\data\tmp\ALD patent background + target paper.pdf,450
9a856a611d11fc886f414660bf0cc1aa,Ethanol,19,app\data\tmp\ALD patent background + target paper.pdf,451
cec105d16bd231173580b4a77b6e1b73,Control,19,app\data\tmp\ALD patent background + target paper.pdf,452
b0025b9d8ccf1fa259b183aa2a316c67,Ethanol,19,app\data\tmp\ALD patent background + target paper.pdf,453
2b1f8cab3c91b40014cd4a058e53b0e8,Extended Data Fig. 5 | See next page for caption.,19,app\data\tmp\ALD patent background + target paper.pdf,454
31ebfc134ca8573c24714f760109f2ec,"2 PBS C. crescentus phages WT 5 E. faecalis phages Ethanol PBS g ; (17.92%) C. crescentus phages Atpdasus PC2 i E. faecalis phages B 0.4 0 5 PC1 (g'z.as%)

Cyp2e1 & S = § - S P = F 1.0 B Fold change 0.5 il E I i 0.0 WT wT AMSIISI AMSI/SI Control Ethanol",19,app\data\tmp\ALD patent background + target paper.pdf,455
ea808df864a580ae6835118fb494ee0a,Article,20,app\data\tmp\ALD patent background + target paper.pdf,456
09c0906cf9bb00c63ea34a39c1149d63,"Extended Data Fig. 5 | Phages reduce translocation of cytolysin to the liver and reduce ethanol-induced liver disease in Atp4aSl/Sl mice. a–k, Wild-type (WT) and Atp4aSl/Sl littermates were fed oral isocaloric (control) or chronic– binge ethanol diets, and gavaged with vehicle (PBS), control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. a, Serum levels of ALT. b, Hepatic triglyceride",20,app\data\tmp\ALD patent background + target paper.pdf,457
78fc3edc0921c36777058a6fe203e1b5,"content. c, Representative oil red O-stained liver sections. d–f, Hepatic levels of mRNAs. g, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. h, Faecal CFUs of Enterococcus. i, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant",20,app\data\tmp\ALD patent background + target paper.pdf,458
524634e463313fc4618dd1a30b91247d,"difference in faecal microbiota among mice given PBS, control phage or phages that target cytolytic E. faecalis in each group. j, k, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h, j, k). P values were determined by two-way ANOVA with Tukey’s post hoc test (a, b, d–f, h, j, k), two-sided Fisher’s exact test followed by FDR",20,app\data\tmp\ALD patent background + target paper.pdf,459
5dfd71021dfcfcf1ac796f5dbdedacbc,"procedures (g) or PERMANOVA followed by FDR procedures (i). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",20,app\data\tmp\ALD patent background + target paper.pdf,460
0723f53f4c9a5c2461ed6f56ca7fa138,<. 2. - 8s °s o - Ef5 Ef2,21,app\data\tmp\ALD patent background + target paper.pdf,461
e1cec6ad24369bc760065fffa460d645,Ef2.1,21,app\data\tmp\ALD patent background + target paper.pdf,462
6ef965a3edd91a833496646f02e3d4bc,Ef2.3,21,app\data\tmp\ALD patent background + target paper.pdf,463
6591857596f95955fa51cbef67d21df2,"Ef5.1 F)- ) ) o ol ) ) o o0 (41,141 bp) Ef5.2 (41,418 bp) ) b o s o i o 4 0 D Ef5.3 F)-) b ) o ol e ) om0 ) (39,115 bp) Ef5.4 (41,141 bp) WD) e om0 Ef2.1 (140,938 bp) PP ) o o ) ) s o ) ) o ) DO DO O OO 0 OO0 o ™ ¢ Ef2.2 (R b e W W D A (58,400 bp) LB Ef2.3 i oo e ) ) o ) (147,289 bp) ) ) ) m) m) )mm) oou omno mmm mao Capsid structural components Tail and baseplate and assembly assembly e [ |:| encapsidation/terminase [ tail fibers - DNA polymerase - endolysin/lysin - hypothetical protein (]",21,app\data\tmp\ALD patent background + target paper.pdf,464
4ca347fd483d3191b486dbaf530e2f8e,major capsid - tail component [ DNA binding I holin [ intron/intein I rortal [ tail measure ] DNA recombination |:| regulatory [ protease (scaffold protein) I salvage of [ transcription factor nucleosides and Il other nucleotides |:| other known functions ] DNA restriction/ modification e tRNA |:| nucleotide degradation,21,app\data\tmp\ALD patent background + target paper.pdf,465
5a46d65e5a29d5ef62ca77f294c2f6d6,"Extended Data Fig. 6 | Isolation and amplification of phages against cytolytic E. faecalis strains isolated from patients with alcoholic hepatitis. a, BHI agar plates showing phage plaque morphology. b, Transmission electron microscopy graphs of myophages Ef2.1 and Ef2.3, stained with phosphotungstic acid showing contracted tails. c, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage",21,app\data\tmp\ALD patent background + target paper.pdf,466
216d750c1bd4d36381d34073b8323981,"genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional role categories. Sequences that encode tRNA genes are indicated by a cloverleaf structure. Scale bar, 50 nm. All results were generated from at least three independent replicates.",21,app\data\tmp\ALD patent background + target paper.pdf,467
4fad559b74085297dc73a31587d915b9,"Article

a",22,app\data\tmp\ALD patent background + target paper.pdf,468
286c49c6f34e6bea26025f1839751a71,"TUNEL C. crescentus phages Cytolysin-positive E. faecalis phages kK Kk C. crescentus phages "" EEnm Cytolysin-positive E. faecalis phages Percent positive (%) Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol",22,app\data\tmp\ALD patent background + target paper.pdf,469
8b826f09519ddadbd726b17ba49e0539,"""",22,app\data\tmp\ALD patent background + target paper.pdf,470
74abd6674f75088e8049487311875a06,o0 e o Control 1 [0 e i s A o ] Ethanol S » C. crescentus phages Cytolysin-positive C. crescentus phages Cytolysin-osn ive E. faecalis phages E. faecalis phages Patient #5 Patient #2,22,app\data\tmp\ALD patent background + target paper.pdf,471
ef3da57f62941ab588d86b2c9cb824ff,Patient #2,22,app\data\tmp\ALD patent background + target paper.pdf,472
19cc01519bb95a0302c75f0c32acda64,"Cxcl2 [T .\ "" Fold change - o H al E Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

Acta2 10 I:. Fold change Py Og B o Ho ¥ Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

Fecal Enterococcus 1010 10° 2108 O 107 108 108 | Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol",22,app\data\tmp\ALD patent background + target paper.pdf,473
157ba01624f2f006cbee299f8f1f0545,Control C. crescentus phages 5 Cytolysin-positive E. faecalis phages | Patient #5 (=) o C. crescentus phages J Cytolysin-positive E. faecalis phages I Patient #2 =] o PC2 (7.13%) -0.5 -1.0 -0.5 Poc'? (80.98%) 0,22,app\data\tmp\ALD patent background + target paper.pdf,474
b57294411d568c83137df484ad080dd9,J,22,app\data\tmp\ALD patent background + target paper.pdf,475
72a69c838af0ea388e33510eb364dc7b,"Ethanol C. crescentus phages 0.25 Cytolysin-positive E. faecalis phages Patient #5 C. crescentus phages Patient #2 LILILIL) Cytolysin-positive E. faecalis phages § PC2 (16.3%) ::n -0.25 0.25 Pc1°tgoz.44%)

Serum ethanol 800 o 60 "" = 400 % 20 LE Patient Patient #5 #2 Ethanol

Adh1 2.0 - - o oo o - ] Fold change 0.5 i I. : i 0.0 Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol",22,app\data\tmp\ALD patent background + target paper.pdf,476
4c442217ef6492987ac4deefb8d6ba62,"Extended Data Fig. 7 | Phages that target cytolytic E. faecalis reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (faeces from one patient were also used in Fig. 2). The mice were then fed oral isocaloric (control) or chronic–binge ethanol diets, and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of 3 or 4 different phages that target cytolytic",22,app\data\tmp\ALD patent background + target paper.pdf,477
15eaa7e036239396c4063b37977757e6,"E. faecalis (1010 PFUs), one day before an ethanol binge. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the inflammatory cytokine Cxcl2, and Acta2 (a marker of activated hepatic stellate cells). e, Faecal CFUs of Enterococcus. f, Faecal samples were",22,app\data\tmp\ALD patent background + target paper.pdf,478
354b05d34dd5dd5c42af859f8edad82d,Cyp2e1 s l-. = o Oo [ T - = o Fold change 0.5 | 0.0 Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol,22,app\data\tmp\ALD patent background + target paper.pdf,479
86a22b341eac11d9f3a2d4a5aa15b7e7,"collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices shows no significant differences in the faecal microbiota of mice gavaged with control phage and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c–e, g, h). P values were determined by two-way",22,app\data\tmp\ALD patent background + target paper.pdf,480
c1ee52110515f47f5c39ec5427cf9b4b,"ANOVA with Tukey’s post hoc test (a, c–e, g, h) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, ***P < 0.001.",22,app\data\tmp\ALD patent background + target paper.pdf,481
fb2e6d7638f2bc6112ad82d303b5bd45,"® %, H %‘Y % % %é 84 S s s""_s.’.f X %3 s By 3 g 3 % Eg g H £ o S & X3 23 & F o §¢‘ 5%, 8% 2, o 2 o Yo, s, 5, 2. & s e, & B8, By ®- N ) S <1 P G %, A 2. g5eC Ef54 PhiM1EE, o‘% Efal Ef6 VB-EfaM-£f2.3 vB-EfaSEfS PhiEF17H. PMBT2 vB-EfaM-Ef2.1: -vB-EfaS-Ef5.2 PhiEF24C P2\ Si pm,,.awrmae AS%/% B, EfaP_in1gg KA s 'aezsop“, A e S S, 103 & 253 o o, 62 ¥ & S, S, - kN N & 6 %, NG [ Siphoviridae S POt ne 5 % N & § N N g3 & N % . Podoviridae é\‘ §‘§ % Uﬂ(\l gﬂ‘f;%z k) g g Ef7 B Myoviridae j‘%""‘* Tree scale:",23,app\data\tmp\ALD patent background + target paper.pdf,482
2cf01531416b8d3d70e65924aa558c6b,1 %,23,app\data\tmp\ALD patent background + target paper.pdf,483
f37122793e3327d6d21c459d7874359f,"Ef6.1 ) b e o om0 4 (40,429 bp) Ef6.2 (17,966 bp) ) o Ef6.3 ) oo (18,136 bp) Ef6.4 ) s ) o fmmn o m mn mb 0 (41,133 bp) Ef7.1 D b ) B | I (58,018 bp) O MmN - Ef7.2 1 ) o s 4 (18,737 bp) Ef7.3 ) oo (18,818 bp) Ef7.4 O i (18,415 bp) apsid structural components Other N and assembly |:| encapsidation/terminase [ tail fibers - DNA polymerase [ endolysin/ysin | [l hypothetical protein - tail component I intron/intein - major capsid [ DNA binding [ holin I portal [ tail measure [ regulatory ] DNA",23,app\data\tmp\ALD patent background + target paper.pdf,484
7ccd7e4153fdce5385f3c3e6bde74c4f,recombination [l protease (scaffold protein) I salvage of = RNA Il other nucleosides and nucleotides [] DNA restriction/ modification (| nucleotide degradation,23,app\data\tmp\ALD patent background + target paper.pdf,485
4d4266c9d2658a14902b350d2009ee26,C,23,app\data\tmp\ALD patent background + target paper.pdf,486
7ffd4d09317a3aa004b9355b4784fea9,Extended Data Fig. 8 | See next page for caption.,23,app\data\tmp\ALD patent background + target paper.pdf,487
2f12ee92767a68c3e01ef50a040d737d,Article,24,app\data\tmp\ALD patent background + target paper.pdf,488
586cf2d6351e72a05ebc838fef8621e2,"Extended Data Fig. 8 | Isolation and amplification of phages against non- cytolytic E. faecalis strains isolated from patients with alcoholic hepatitis. a, BHI agar plates showing phage plaque morphology. b, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional",24,app\data\tmp\ALD patent background + target paper.pdf,489
e0da2f282cd9777db1bcec5d89c5ca38,"role categories. Sequences that encode tRNA genes are indicated by a cloverleaf structure. c, Phylogenetic tree of Enterococcus phages. A whole-genome average nucleotide distance tree was constructed for 73 available Enterococcus phage genomes: 54 of these were",24,app\data\tmp\ALD patent background + target paper.pdf,490
4baaa4d3e7d55822b599edb927ee8215,from GenBank (denoted by black letters) and 19 were from this study (4 phages against cytolysin-positive E. faecalis isolated from mice (shown in blue letters); 7 phages against cytolysin-positive E. faecalis isolated from patients with alcoholic hepatitis (shown in pink letters); and 8 phages against cytolysin- negative E. faecalis isolated from patients with alcoholic hepatitis (shown in green letters)) with Mash43 using a sketch size of s = 5000 and a k-mer size of k = 12 and GGRaSP59,24,app\data\tmp\ALD patent background + target paper.pdf,491
052373928fd2ae03310a7c0b3d2a00e6,"(Methods). Coloured branches denote specific phage genera or subfamily: Sap6virus, P68virus and Spounavirinae. The scale bar represents per cent average nucleotide divergence. All results were generated from at least three independent replicates.",24,app\data\tmp\ALD patent background + target paper.pdf,492
e87dceed4c989301dfb7bd4580ba1676,TUNEL C. crescentus phages Cytolysin-negative E. faecalis phages C. crescentus phages LI B | Cytolysin-negative E. faecalis phages Percent positive (%) | Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,app\data\tmp\ALD patent background + target paper.pdf,493
82fc3527e8e858dfffceb0488361d61f,|,25,app\data\tmp\ALD patent background + target paper.pdf,494
01dbe5f8c67099a761b4e0e496a50400,"Lo Y\ % i o Control 2 g.;ﬁ‘ % o “ . LA ‘.,‘;‘ ok - -4 & Aal f:v Ethanol i 3 s 4 ;j C. crescentus phages ytolysin-positive C. crescentus phages Cﬁolysin-pos ve E. faecalis phages E. faecalis phages Patient #6 Patient #7

Cxcl2 (L] Ll oo Fold change 0 ] i Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol

Acta2 Ll "" Fold change T el ] b g i i Patient Patient Patient Patient #6 H#7 #6 H7 Control Ethanol",25,app\data\tmp\ALD patent background + target paper.pdf,495
db448b59b09ec053ce6e1e4778a10f51,Liver cylLg 100 =3 =3 o o B o Percent mice (%) N =3 nd nd nd nd nd nd nd nd [~ Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,app\data\tmp\ALD patent background + target paper.pdf,496
b31211b94c9867a9f070ff684d62c5c5,Control,25,app\data\tmp\ALD patent background + target paper.pdf,497
35e5fabe9395b70360871fc92df6f0df,Ethanol,25,app\data\tmp\ALD patent background + target paper.pdf,498
8c5277a67c8cc3e257a914ee44d92094,"Control 1.0 C. crescentus phages g Cytolysin-positive E. faecalis phages | Patient #6 2 C. crescentus phages Cytolysin-positive E. faecalis phages | Patient #7 g : ] PC2 (19.54%) b -0.5 -1.0 -1.0 1.0 : PC1 (35?34%)

Ethanol . - C. crescentus phages Cytolysin-positive E. faecalis phages | Patient #6 0.3 C. crescentus phages u[m|n|n| Cytolysin-positive E. faecalis phages | Patient #7 0.0 PC2 (15.2%) -0.3 -0.2 0.2 0.50 P&o(oss.sa%)",25,app\data\tmp\ALD patent background + target paper.pdf,499
a6c20ca48aeaaa0d21f3e47aa18d60e1,"Serum ethanol 1,000 800 . (1] "" 600 .-II (mgr/dl) 400 200 Patient Patient #6 #7 Ethanol

Adh1 25 20 - L LT - o was Fold change g & i i S Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol",25,app\data\tmp\ALD patent background + target paper.pdf,500
e0d0b24b2bdd3edd4a205c7d1aeae1eb,"Extended Data Fig. 9 | Phages that target non-cytolytic E. faecalis do not reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis. Transplanted gnotobiotic mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages targeting non-cytolytic E. faecalis (1010 PFUs),",25,app\data\tmp\ALD patent background + target paper.pdf,501
5253416850d1742490f9c086f6d64d74,"1 day before an ethanol binge. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the inflammatory cytokine Cxcl2, and Acta2 (a marker of activated hepatic stellate cells). e, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. f, Faecal samples were collected and 16S rRNA",25,app\data\tmp\ALD patent background + target paper.pdf,502
d3a595610f2c6a926c765429519f1602,Cyp2e1 25 2.0 On - . e - o Fold change = o Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,app\data\tmp\ALD patent background + target paper.pdf,503
c4e0a2f3dd79e168e420d316aceaa741,"genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant difference in faecal microbiota among mice gavaged with control phages and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, g, h). P values were determined by two-way ANOVA with Tukey’s post",25,app\data\tmp\ALD patent background + target paper.pdf,504
887d896ab1169bc8b00ce94c23d3fad3,"hoc test (a, c, d, g, h), two-sided Fisher’s exact test followed by FDR procedures (e) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",25,app\data\tmp\ALD patent background + target paper.pdf,505
94626496bba9f17c252002a800b76698,natureresearch,26,app\data\tmp\ALD patent background + target paper.pdf,506
6241f07d7fbd4a8e5d0917e832ca411c,Reporting Summary,26,app\data\tmp\ALD patent background + target paper.pdf,507
d65262b1ff571b846a2a49a82f584534,"Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.",26,app\data\tmp\ALD patent background + target paper.pdf,508
9ad2360a18d91bbfbaab606c61c58714,Statistics,26,app\data\tmp\ALD patent background + target paper.pdf,509
4f54bf860129da0c86ea4220bd7aeabf,"For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described",26,app\data\tmp\ALD patent background + target paper.pdf,510
5831bedf496d848f6c82c63525bdf8bf,"solely by name; describe more complex techniques in the Methods section. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis",26,app\data\tmp\ALD patent background + target paper.pdf,511
050549609d7c690be32eb02d98780226,"testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable. For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated",26,app\data\tmp\ALD patent background + target paper.pdf,512
a1f51c4dac11f056353b466aa1fb7764,Our web collection on statistics for biologists contains articles on many of the points above.,26,app\data\tmp\ALD patent background + target paper.pdf,513
f88c631ed62fb67bd5f3eee7b705f2f7,"Software and code

Policy information about availability of computer code",26,app\data\tmp\ALD patent background + target paper.pdf,514
dc28e83c26e506bd05e0188bd3da009d,Data collection All biochemical assays were measured using SoftMax Pro 7.0.3; gPCRs were run with StepOnePlus real-time PCR system; Liver histological pictures were taken with DP Controller and DP Manager (Olympus); Phage electronic microscopy pictures were taken using Maxim DL5; Plates were scanned using EPSON 4990 Photo; All pictures were viewed using ImageJ,26,app\data\tmp\ALD patent background + target paper.pdf,515
7824d8d62eba52865ffdf7ddd3ffada6,Data analysis,26,app\data\tmp\ALD patent background + target paper.pdf,516
c0eac14d330c63a2951758061dcc99f2,"Bacteriophage sequencing and phage tree: Albacore v2.3.4 (ONT), Porechop v0.2.3, Unicycler v0.4.7 pipeline, Pilon v1.22, CLC Genomics Workbench 4.9, NCBI Prokaryotic Genome Annotation Pipeline, in-house PERL script using Xfig, Phage_Finder, MASH program, GGRaSP and APE R-package, iTOL tree viewer 16S sequencing: MOTHUR-based 16S rDNA analysis workflow E. faecalis genome sequencing and tree: abricate v0.8.10 , Prokka, Roary, RAXML, iTOL Statistical analyses: R",26,app\data\tmp\ALD patent background + target paper.pdf,517
a24abc7b5748c7278ccaaeab6c04d6f4,"statistical software 3.5.1, GraphPad Prism v6.01",26,app\data\tmp\ALD patent background + target paper.pdf,518
63c12506dc05c9829936083066022bcf,"For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.",26,app\data\tmp\ALD patent background + target paper.pdf,519
c7cff159ef73b4d2f710bfd05441e64a,"Data

Policy information about availability of data",26,app\data\tmp\ALD patent background + target paper.pdf,520
d9a8ba96be29b5f791e5abd31b14cc39,"All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets",26,app\data\tmp\ALD patent background + target paper.pdf,521
1d770d1e764c4463a0a602356e2c2629,- A list of figures that have associated raw data,26,app\data\tmp\ALD patent background + target paper.pdf,522
56cca4b175df37420989d343ff3be21f,- A description of any restrictions on data availability,26,app\data\tmp\ALD patent background + target paper.pdf,523
f5a19505693b0a3ce66427b7d0313510,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Bacteriophage raw sequence reads and annotated genomes are,26,app\data\tmp\ALD patent background + target paper.pdf,524
d68360e15ff04f720a7c345bcefd4c9c,Corresponding author(s): Bernd Schnabl,26,app\data\tmp\ALD patent background + target paper.pdf,525
ac453671710a42f7eb22b5ebc238befb,"Last updated by author(s): Sep 5, 2019",26,app\data\tmp\ALD patent background + target paper.pdf,526
b0b1f806e834c0012cc0391d1ef5d5db,n  a  t  u  r  e     r  e  s  e  a  r  c  h        |        r  e  p  o  r  t  i  n  g     s  u  m  m  a  r  y  O  c  t  o  b  e  r     2  0  1  8  1 ,26,app\data\tmp\ALD patent background + target paper.pdf,527
7df743a9d402d7aa008736c058236c9f,n  a  t  u  r  e     r  e  s  e  a  r  c  h        |        r  e  p  o  r  t  i  n  g     s  u  m  m  a  r  y  O  c  t  o  b  e  r     2  0  1  8  2 ,27,app\data\tmp\ALD patent background + target paper.pdf,528
8d6d0754209bfa8b42de5ee666f2da21,available at NCBI under the following consecutive BioSample IDs (SAMN11089809 – SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at ENA under Study PRJEB25007.,27,app\data\tmp\ALD patent background + target paper.pdf,529
b00ec0c039d11f10962d125b56d014a2,Field-specific reporting,27,app\data\tmp\ALD patent background + target paper.pdf,530
ed4eb6283b3b3cc6a5a8290d27f54ba7,"Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf",27,app\data\tmp\ALD patent background + target paper.pdf,531
3f140aac5ac40e750888f6b2bdcc6575,Life sciences study design,27,app\data\tmp\ALD patent background + target paper.pdf,532
7a2b01ed896550c8117087fc7824fd2a,All studies must disclose on these points even when the disclosure is negative.,27,app\data\tmp\ALD patent background + target paper.pdf,533
f8fb4b6adf4e8912817aafe2537d293b,"Sample size No power analyses or other calculations were used to predetermine sample sizes. Sample sizes were chosen based on prior literature using similar experimental paradigms (Nat Commun. 2017;8:2137; Gut. 2019;68:1504-1515) Data exclusions No data were excluded Replication In vivo experiments: more than two technical replicates (from different cohorts, on different dates), as well as biological replicates were performed to ensure data reproducibility; In vitro experiments: three",27,app\data\tmp\ALD patent background + target paper.pdf,534
a5a39a6be862a395cd7ce33a26a846a4,independent experiments and also replicates were performed on different dates to ensure data reproducibility. All replications were successful. Randomization Mice of similar age and weight were randomly assigned to experimental and control groups. Blinding The investigators were not blinded during cell and animal experiment assays.,27,app\data\tmp\ALD patent background + target paper.pdf,535
7f405f826ac348842ffdbbb7414e4e8e,"Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.",27,app\data\tmp\ALD patent background + target paper.pdf,536
e4c19235e2a849bd4f6878e3c5731f1a,Materials & experimental systems Methods n/a Involved in the study n/a Involved in the study Antibodies ChIP-seq Eukaryotic cell lines Flow cytometry Palaeontology MRI-based neuroimaging Animals and other organisms Human research participants Clinical data,27,app\data\tmp\ALD patent background + target paper.pdf,537
1079623d09f88cbad631311ab63101b6,Animals and other organisms,27,app\data\tmp\ALD patent background + target paper.pdf,538
4f6a45dc206060211b75dc46f988ad09,"Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Female and male C57BL/6 mice (age, 9-12 weeks) (strain: wild type, Atpdasl/sl) Wild animals No wild animals were involved in the study. Field-collected samples No field-collected samples were involved in the study",27,app\data\tmp\ALD patent background + target paper.pdf,539
d7ecf5525d69b0f24323ed99801783ab,"Ethics oversight All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.",27,app\data\tmp\ALD patent background + target paper.pdf,540
2a92c84eeb4c19965402473160c6652c,Note that full information on the approval of the study protocol must also be provided in the manuscript.,27,app\data\tmp\ALD patent background + target paper.pdf,541
a78a4466501beb67df4d099dd88568b0,"Human research participants

Policy information about studies involving human research participants",27,app\data\tmp\ALD patent background + target paper.pdf,542
8e8d93361fb65620493a69e1431b6f31,Population characteristics,27,app\data\tmp\ALD patent background + target paper.pdf,543
21faa980fbea7e7f18b5cc59e8cf98db,"Alcoholic hepatitis patients were from multiple centers from United States, Mexico and Europe, with the age ranged from 30 to",27,app\data\tmp\ALD patent background + target paper.pdf,544
282fa577e826fe71b6c003fe11459382,"Population characteristics 75. Alcohol use disorder patients and non-alcoholic controls were from United States and Europe, with the age ranged from 27 to 74. Both genders were included in all populations. Detailed descriptions in Methods, Extended Data Tables 1 and 2",28,app\data\tmp\ALD patent background + target paper.pdf,545
f3f5e50d509ccbdf913a2b08463b52cc,Recruitment,28,app\data\tmp\ALD patent background + target paper.pdf,546
538e036893f09aeb4bb06034b1aca44a,"Patients with alcohol use disorder fulfilling the DSM IV criteria (J Abnorm Psychol. 1997;106:545-553) were recruited from an alcohol withdrawal unit in San Diego, USA and Brussels, Belgium where they followed a detoxification and rehabilitation program. Alcoholic hepatitis patients were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centers in the USA, Mexico, United Kingdom, France and Spain. Detailed inclusion and",28,app\data\tmp\ALD patent background + target paper.pdf,547
b5756955c58bb439e8ba7454f785c352,exclusion criteria are listed in Methods,28,app\data\tmp\ALD patent background + target paper.pdf,548
2242c673399a0b701a7d20a9bad3d5ad,Ethics oversight,28,app\data\tmp\ALD patent background + target paper.pdf,549
1fc100478613ab56cb3dca8978c6d0ba,"The protocol was approved by the Ethics Committee of Hopital Huriez (Lille, France), Universidad Autonoma de Nuevo Leon (Monterrey, México), Hospital Universitari Vall d'Hebron (Barcelona, Spain), King's College London (London, UK), Yale University (New Haven, USA), University of North Carolina at Chapel Hill (Chapel Hill, USA), Weill Cornell Medical College (New York, USA), Columbia University (New York, USA), University of Wisconsin (Madison, USA), VA San Diego",28,app\data\tmp\ALD patent background + target paper.pdf,550
ed2291721954ac35d01d81af665454a2,"Healthcare System (San Diego, USA) and Université Catholique de Louvain (Brussels, Belgium).",28,app\data\tmp\ALD patent background + target paper.pdf,551
3e13776b673bbc0204248f20759c767c,Note that full information on the approval of the study protocol must also be provided in the manuscript.,28,app\data\tmp\ALD patent background + target paper.pdf,552
84526874552828c5ea1aa0d20dd2e0ba,n  a  t  u  r  e     r  e  s  e  a  r  c  h        |        r  e  p  o  r  t  i  n  g     s  u  m  m  a  r  y  O  c  t  o  b  e  r     2  0  1  8  3 ,28,app\data\tmp\ALD patent background + target paper.pdf,553
